Document_and_Entity_Informatio
Document and Entity Information | 3 Months Ended | |
Mar. 31, 2014 | 9-May-14 | |
Document and Entity Information [Abstract] | ' | ' |
Entity Registrant Name | 'BIOTIME INC | ' |
Entity Central Index Key | '0000876343 | ' |
Current Fiscal Year End Date | '--12-31 | ' |
Entity Well-known Seasoned Issuer | 'No | ' |
Entity Voluntary Filers | 'No | ' |
Entity Current Reporting Status | 'Yes | ' |
Entity Filer Category | 'Accelerated Filer | ' |
Entity Common Stock, Shares Outstanding | ' | 72,149,329 |
Document Fiscal Year Focus | '2014 | ' |
Document Fiscal Period Focus | 'Q1 | ' |
Document Type | '10-Q | ' |
Amendment Flag | 'false | ' |
Document Period End Date | 31-Mar-14 | ' |
CONDENSED_CONSOLIDATED_BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (USD $) | Mar. 31, 2014 | Dec. 31, 2013 |
CURRENT ASSETS | ' | ' |
Cash and cash equivalents | $6,637,834 | $5,495,478 |
Inventory | 236,588 | 178,694 |
Trade accounts and grants receivable, net | 818,275 | 998,393 |
Prepaid expenses and other current assets | 1,554,114 | 1,277,405 |
Total current assets | 9,246,811 | 7,949,970 |
Equipment, net | 2,959,150 | 2,997,733 |
Deferred license and consulting fees | 418,958 | 444,833 |
Deposits | 428,827 | 129,129 |
Other long-term assets | 56,062 | 0 |
Intangible assets, net | 44,840,087 | 46,208,085 |
TOTAL ASSETS | 57,949,895 | 57,729,750 |
CURRENT LIABILITIES | ' | ' |
Accounts payable and accrued liabilities | 5,443,063 | 6,722,624 |
Deferred license and subscription revenue, current portion | 177,594 | 235,276 |
Total current liabilities | 5,620,657 | 6,957,900 |
LONG-TERM LIABILITIES | ' | ' |
Deferred rent, net of current portion | 28,054 | 35,997 |
Deferred tax liability, net | 6,928,522 | 8,277,548 |
Other long term liabilities | 8,441 | 195,984 |
Total long-term liabilities | 6,965,017 | 8,509,529 |
Commitments and contingencies | ' | ' |
EQUITY | ' | ' |
Preferred shares, no par value, authorized 2,000,000 shares as of March 31, 2014 and December 31, 2013; 70,000 and nil issued and outstanding as of March 31, 2014 and December 31, 2013, respectively | 3,500,000 | 0 |
Common shares, no par value, authorized 125,000,000 shares as of March 31, 2014 and December 31, 2013; 69,617,329 issued and 59,071,192 outstanding as of March 31, 2014 and 67,412,139 issued and 56,714,424 outstanding at December 31, 2013 | 211,943,421 | 203,456,401 |
Contributed capital | 93,972 | 93,972 |
Accumulated other comprehensive income/(loss) | -44,341 | 62,899 |
Accumulated deficit | -153,877,561 | -145,778,547 |
Treasury stock at cost: 10,546,137 and 10,697,715 shares at March 31, 2014 and at December 31, 2013, respectively | -42,372,546 | -43,033,957 |
Total shareholders' equity | 19,242,945 | 14,800,768 |
Noncontrolling interest | 26,121,276 | 27,461,553 |
Total equity | 45,364,221 | 42,262,321 |
TOTAL LIABILITIES AND EQUITY | $57,949,895 | $57,729,750 |
CONDENSED_CONSOLIDATED_BALANCE1
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) (USD $) | Mar. 31, 2014 | Dec. 31, 2013 |
EQUITY | ' | ' |
Preferred shares, par value (in dollars per share) | $0 | $0 |
Preferred shares, authorized (in shares) | 2,000,000 | 2,000,000 |
Preferred shares, issued (in shares) | 70,000 | 0 |
Preferred shares outstanding (in shares) | 70,000 | 0 |
Common shares, par value (in dollars per share) | $0 | $0 |
Common shares, authorized (in shares) | 125,000,000 | 125,000,000 |
Common shares, issued (in shares) | 69,617,329 | 67,412,139 |
Common shares, outstanding (in shares) | 59,071,192 | 56,714,424 |
Treasury stock (in shares) | 10,546,137 | 10,697,715 |
CONDENSED_CONSOLIDATED_STATEME
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) (USD $) | 3 Months Ended | |
Mar. 31, 2014 | Mar. 31, 2013 | |
REVENUES: | ' | ' |
License fees | $294,504 | $349,824 |
Royalties from product sales | 97,886 | 107,599 |
Grant income | 575,659 | 90,326 |
Sale of research products | 98,586 | 66,724 |
Total revenues | 1,066,635 | 614,473 |
Cost of sales | -131,914 | -182,749 |
Total revenues, net | 934,721 | 431,724 |
EXPENSES: | ' | ' |
Research and development | -8,405,393 | -5,395,488 |
General and administrative | -3,667,171 | -3,416,145 |
Total expenses | -12,072,564 | -8,811,633 |
Loss from operations | -11,137,843 | -8,379,909 |
OTHER INCOME/(EXPENSES): | ' | ' |
Interest (expense)/income, net | -8,384 | 943 |
Loss on sale of fixed assets | -8,576 | -1,523 |
Other income/(expense), net | 77,746 | -28,056 |
Total other income/(expense), net | 60,786 | -28,636 |
LOSS BEFORE INCOME TAX BENEFIT | -11,077,057 | -8,408,545 |
Income tax benefit | 1,349,026 | 0 |
NET LOSS | -9,728,031 | -8,408,545 |
Net loss attributable to noncontrolling interest | 1,629,017 | 689,282 |
NET LOSS ATTRIBUTABLE TO BIOTIME, INC. | -8,099,014 | -7,719,263 |
Foreign currency translation (loss)/gain | -104,590 | 148,437 |
Unrealized loss on available-for-sale securities, net | -2,650 | 0 |
COMPREHENSIVE LOSS | ($8,206,254) | ($7,570,826) |
BASIC AND DILUTED LOSS PER COMMON SHARE (in dollars per share) | ($0.14) | ($0.15) |
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: BASIC AND DILUTED (in shares) | 58,257,427 | 51,175,649 |
CONDENSED_CONSOLIDATED_STATEME1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (USD $) | 3 Months Ended | |
Mar. 31, 2014 | Mar. 31, 2013 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ' | ' |
Net loss attributable to BioTime, Inc. | ($8,099,014) | ($7,719,263) |
Adjustments to reconcile net loss attributable to BioTime, Inc. to net cash used in operating activities: | ' | ' |
Depreciation expense | 256,945 | 113,356 |
Amortization of intangible assets | 1,367,998 | 642,573 |
Amortization of deferred consulting fees | 16,279 | 16,280 |
Amortization of deferred license fees | 27,375 | 27,375 |
Amortization of deferred rent | -5,040 | -2,222 |
Amortization of deferred license, royalty and subscription revenues | -280 | -42,996 |
Amortization of stock-based prepaid rent | 21,146 | 0 |
Net loss allocable to non-controlling interest | -1,629,017 | -689,282 |
Stock-based compensation | 801,554 | 691,946 |
Deferred income tax benefit | -1,349,026 | 0 |
Loss on sale or write-off of equipment | 8,576 | 1,523 |
Deferred revenues | -57,402 | 0 |
Changes in operating assets and liabilities: | ' | ' |
Accounts receivable, net | -24,441 | -82,916 |
Grant receivable | 202,122 | 371,886 |
Inventory | -57,894 | 2,981 |
Prepaid expenses and other current assets | -375,224 | -243,798 |
Accounts payable and accrued liabilities | -1,276,211 | -101,319 |
Other long term liabilities | -185,717 | -7,806 |
Net cash used in operating activities | -10,357,271 | -7,021,682 |
CASH FLOWS FROM INVESTING ACTIVITIES: | ' | ' |
Purchase of equipment | -231,921 | -496,128 |
Security deposit paid, net | -299,697 | -54,423 |
Proceeds from the sale of equipment | 4,000 | 0 |
Cash used in investing activities | -527,618 | -550,551 |
CASH FLOWS FROM FINANCING ACTIVITIES: | ' | ' |
Employee options exercised | 12,500 | 0 |
Director options exercised | 46,000 | 0 |
Proceeds from issuance of common shares | 8,182,559 | 11,699,340 |
Fees paid on sale of common shares | -212,046 | -319,625 |
Proceeds from sale of treasury shares | 599,472 | 1,602,921 |
Proceeds from sale of preferred stock | 3,500,000 | 0 |
Proceeds from sale of common shares of subsidiary | 0 | 130,502 |
Net cash provided by financing activities | 12,128,485 | 13,113,138 |
Effect of exchange rate changes on cash and cash equivalents | -101,240 | 5,463 |
NET CHANGE IN CASH AND CASH EQUIVALENTS: | 1,142,356 | 5,546,368 |
CASH AND CASH EQUIVALENTS: | ' | ' |
At beginning of the period | 5,495,478 | 4,349,967 |
At end of the period | 6,637,834 | 9,896,335 |
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | ' | ' |
Cash paid during the period for interest | 8,472 | 0 |
SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND INVESTING ACTIVITIES: | ' | ' |
Common shares issued for consulting services | 0 | 77,280 |
Common shares issued for rent | $0 | $242,720 |
Organization_Basis_of_Presenta
Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies | 3 Months Ended | |||
Mar. 31, 2014 | ||||
Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies [Abstract] | ' | |||
Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies | ' | |||
1. Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies | ||||
General – BioTime is a biotechnology company engaged in two areas of biomedical research and product development. BioTime's primary focus is in the field of regenerative medicine; specifically human embryonic stem (“hES”) cell and induced pluripotent stem (“iPS”) cell technology. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. BioTime and its subsidiaries plan to develop stem cell products for research and therapeutic use. Asterias Biotherapeutics, Inc. (“Asterias”) acquired the stem cell assets of Geron Corporation (“Geron”) that had been used in Geron’s hES cell research and development programs for the development of products for human therapeutics in the following fields: neurology, oncology, orthopedics, and heart failure and myocardial infarction. OncoCyte Corporation (“OncoCyte”) is developing products and technologies to diagnose cancer. ES Cell International Pte Ltd. (“ESI”), a Singapore private limited company, and BioTime’s ESI BIO division are marketing hES cell lines and stem cell related research products in domestic and over-seas markets. OrthoCyte Corporation (“OrthoCyte”) is developing therapies to treat orthopedic disorders, diseases and injuries. ReCyte Therapeutics, Inc. (“ReCyte Therapeutics”) is developing therapies to treat a variety of cardiovascular and related ischemic disorders, as well as products for research using cell reprogramming technology. Cell Cure Neurosciences Ltd. (“Cell Cure Neurosciences”) is an Israel-based biotechnology company focused on developing stem cell-based therapies for retinal and neurological disorders, including the development of retinal pigment epithelial cells for the treatment of macular degeneration, and treatments for multiple sclerosis. LifeMap Sciences, Inc. (“LifeMap Sciences”) markets, sells and distributes GeneCards®, the leading human gene database and an integrated database suite that includes GeneCards®, the LifeMap Discovery® database of embryonic development, stem cell research and regenerative medicine, and MalaCards, the human disease database. | ||||
BioTime is focusing a portion of its efforts in the field of regenerative medicine on the development and sale of advanced human stem cell products and technologies that can be used by researchers at universities and other institutions, at companies in the bioscience and biopharmaceutical industries, and at other companies that provide research products to companies in those industries. Products for the research market generally can be sold without regulatory (FDA) approval, and are therefore relatively near-term business opportunities when compared to therapeutic products. | ||||
BioTime previously developed blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment and other applications. BioTime’s operating revenues are now derived primarily from licensing fees and advertising from the marketing of the LifeMap Sciences database products, from royalties and licensing fees related to the sale of its plasma volume expander product, Hextend®, from the sale of products for research, and from research grants. | ||||
The unaudited condensed consolidated interim balance sheet as of March 31, 2014, the unaudited condensed consolidated interim statements of operations and comprehensive loss for the three months ended March 31, 2014 and 2013, and the unaudited condensed consolidated interim statements of cash flows for the three months ended March 31, 2014 and 2013 have been prepared by BioTime’s management in accordance with the instructions from Form 10-Q and Regulation S-X. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at March 31, 2014 have been made. The consolidated balance sheet as of December 31, 2013 is derived from the Company’s annual audited financial statements as of that date. The results of operations for the three months ended March 31, 2014 are not necessarily indicative of the operating results anticipated for the full year of 2014. | ||||
Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted as permitted by regulations of the Securities and Exchange Commission (“SEC”) except for the consolidated balance sheet as of December 31, 2013, which was derived from audited financial statements. Certain previously furnished amounts have been reclassified to conform with presentations made during the current periods. It is suggested that these condensed consolidated interim financial statements be read in conjunction with the annual audited consolidated financial statements and notes thereto included in BioTime’s Form 10-K for the year ended December 31, 2013. | ||||
Principles of consolidation – BioTime’s consolidated financial statements include the accounts of its subsidiaries. The following table reflects BioTime’s ownership, directly or through one or more subsidiaries, of the outstanding shares of its subsidiaries. | ||||
BioTime | ||||
Subsidiary | Field of Business | Ownership | Country | |
Asterias Biotherapeutics, Inc. | Research, development and commercialization of human therapeutic products from stem cells potentially in the fields of neurology, oncology, orthopedics, and cardiology | 71.60% | USA | |
ES Cell International Pte Ltd | Stem cell products for research, including clinical grade cell lines | 100% | Singapore | |
produced under cGMP | ||||
OncoCyte Corporation | Cancer diagnostics | 75.30% | USA | |
OrthoCyte Corporation | Orthopedic diseases, including chronic back pain and osteoarthritis | 100% | USA | |
Cell Cure Neurosciences Ltd. | Age-related macular degeneration | 62.50% | Israel | |
Multiple sclerosis | ||||
Parkinson’s disease | ||||
ReCyte Therapeutics, Inc. | Vascular disorders, including cardiovascular-related diseases, ischemic conditions, vascular injuries | 94.80% | USA | |
Stem cell-derived endothelial and cardiovascular related progenitor cells for research, drug testing, and therapeutics | ||||
BioTime Asia, Limited | Stem cell products for research | 81% | Hong Kong | |
LifeMap Sciences, Inc. | Genetic, disease, and stem cell databases | 73.20% | USA | |
LifeMap Sciences, Ltd. | Stem cell database | -1 | Israel | |
LifeMap Solutions, Inc. | Mobile health software | -1 | USA | |
-1 | LifeMap Sciences, Ltd. and LifeMap Solutions, Inc. are wholly-owned subsidiaries of LifeMap Sciences, Inc. | |||
All material intercompany accounts and transactions have been eliminated in consolidation. The consolidated financial statements are presented in accordance with accounting principles generally accepted in the U.S. (“GAAP”) and with the accounting and reporting requirements of SEC Regulation S-X. As of March 31, 2014, BioTime consolidated Asterias, ReCyte Therapeutics, OncoCyte, OrthoCyte, ESI, Cell Cure Neurosciences, BioTime Asia, Limited (“BioTime Asia”), LifeMap Sciences, and LifeMap Sciences, Ltd. as BioTime has the ability to control their operating and financial decisions and policies through its ownership, and the noncontrolling interest is reflected as a separate element of equity on BioTime’s condensed consolidated balance sheets. | ||||
Certain significant risks and uncertainties – The operations of BioTime and its subsidiaries are subject to a number of factors that can affect their operating results and financial condition. Such factors include but are not limited to, the following: the results of clinical trials of their respective therapeutic product and medical device candidates; their ability to obtain FDA and foreign regulatory approval to market their respective therapeutic and medical device product candidates; their ability to develop new stem cell research products and technologies; competition from products manufactured and sold or being developed by other companies; the price and demand for their products; their ability to obtain additional financing and the terms of any such financing that may be obtained; their ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products; the availability of ingredients used in their products; and the availability of reimbursement for the cost of their therapeutic products and medical devices (and related treatment) from government health administration authorities, private health coverage insurers, and other organizations. | ||||
Use of estimates – The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. | ||||
Revenue recognition – BioTime complies with SEC Staff Accounting Bulletin guidance on revenue recognition. Royalty revenues consist of product royalty payments. License fee revenues consist primarily of subscription and advertising revenue from our online databases which are recognized based upon respective subscription or advertising periods. Other license fees under certain license agreements were recognized during prior periods when earned and reasonably estimable. Royalties consist primarily of royalties earned on sales of Hextend® and are recognized as revenue in the quarter in which the royalty reports are received from the licensee, rather than the quarter in which the sales took place. When BioTime is entitled to receive up-front nonrefundable licensing or similar fees pursuant to agreements under which BioTime has no continuing performance obligations, the fees are recognized as revenues when collection is reasonably assured. When BioTime receives up-front nonrefundable licensing or similar fees pursuant to agreements under which BioTime does have continuing performance obligations, the fees are deferred and amortized ratably over the performance period. If the performance period cannot be reasonably estimated, BioTime amortizes nonrefundable fees over the life of the contract until such time that the performance period can be more reasonably estimated. Milestone payments, if any, related to scientific or technical achievements are recognized in income when the milestone is accomplished if (a) substantive effort was required to achieve the milestone, (b) the amount of the milestone payment appears reasonably commensurate with the effort expended, and (c) collection of the payment is reasonably assured. Grant income and the sale of research products are recognized as revenue when earned. Revenues from the sale of research products are primarily derived from the sale of hydrogels and stem cell products. | ||||
Cash and cash equivalents – BioTime considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. | ||||
Accounts receivable and allowance for doubtful accounts – Total trade receivables amounted to approximately $600,400 and $575,900 and grants receivable amounted to approximately $334,700 and $539,300 as of March 31, 2014 and December 31, 2013, respectively. Some of these amounts are deemed uncollectible; as such BioTime recognized allowance for doubtful accounts of approximately $116,800 as of March 31, 2014 and December 31, 2013. BioTime evaluates the collectability of its receivables based on a variety of factors, including the length of time receivables are past due and significant one-time events and historical experience. An additional reserve for individual accounts will be recorded if BioTime becomes aware of a customer’s inability to meet its financial obligations, such as in the case of bankruptcy filings or deterioration in the customer’s operating results or financial position. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted. | ||||
Concentrations of credit risk – Financial instruments that potentially subject BioTime to significant concentrations of credit risk consist primarily of cash and cash equivalents. BioTime limits the amount of credit exposure of cash balances by maintaining its accounts in high credit quality financial institutions. Cash equivalent deposits with financial institutions may occasionally exceed the limits of insurance on bank deposits; however, BioTime has not experienced any losses on such accounts. | ||||
Inventory – Inventories are stated at the lower of cost or market. Cost, which includes amounts related to materials, labor, and overhead, is determined in a manner which approximates the first-in, first-out (“FIFO”) method. | ||||
Equipment – Equipment is stated at cost. Equipment is being depreciated using the straight-line method over a period of 36 to 120 months. See Note 3. | ||||
Intangible assets – Intangible assets with finite useful lives are amortized over estimated useful lives and intangible assets with indefinite lives are not amortized but rather are tested at least annually for impairment. Acquired in-process research and development intangible assets are accounted for depending on whether they were acquired as part of an acquisition of a business, or as assets that do not constitute a business. When acquired in conjunction with acquisition of a business, these assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts and are capitalized as an asset. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. However, when acquired in conjunction with an acquisition of assets that do not constitute a business (such as the acquisition of assets from Geron), in accordance with the accounting rules in ASC 805-50, such intangible assets related to in-process research and development (“IPR&D”) are expensed upon acquisition. See Note 8. | ||||
Treasury stock – BioTime accounts for BioTime common shares issued to subsidiaries for future potential working capital needs as treasury stock on the consolidated balance sheet. BioTime has the intent and ability to register any unregistered shares to support the marketability of the shares. | ||||
Warrants to purchase common stock – BioTime generally accounts for warrants issued in connection with equity financings as a component of equity. None of the warrants issued by BioTime as of March 31, 2014 include a conditional obligation to issue a variable number of shares; nor was there a deemed possibility that BioTime may need to settle the warrants in cash. If BioTime were to issue warrants with a conditional obligation to issue a variable number of shares or with the deemed possibility of a cash settlement, BioTime would record the fair value of the warrants as a liability at each balance sheet date and record changes in fair value in other income and expense in the consolidated statements of operations. | ||||
Cost of sales – BioTime accounts for the cost of research products acquired for sale and any royalties paid as a result of any revenues in accordance with the terms of the respective licensing agreements as cost of sales on the condensed consolidated statement of operations. | ||||
Patent costs – Costs associated with obtaining patents on products or technology developed are expensed as general and administrative expenses when incurred. This accounting is in compliance with guidance promulgated by the Financial Accounting Standards Board (the “FASB”) regarding goodwill and other intangible assets. | ||||
Reclassification – Certain prior year amounts have been reclassified to conform to the current year presentation. Trade and grant receivables are now presented in a separate row from prepaid expenses and other current assets. Additionally, we have carved out the loss on sale of fixed assets amount from other expenses. | ||||
Research and development – BioTime complies with FASB requirements governing accounting for research and development costs. Research and development costs are expensed when incurred, and consist principally of salaries, payroll taxes, consulting fees, research and laboratory fees, rent of research facilities, and license fees paid to third parties to acquire patents or licenses to use patents and other technology. | ||||
Foreign currency translation gain and Comprehensive loss – In countries in which BioTime operates, and the functional currency is other than the U.S. dollar, assets and liabilities are translated using published exchange rates in effect at the condensed consolidated balance sheet date. Revenues and expenses and cash flows are translated using an approximate weighted average exchange rate for the period. Resulting translation adjustments are recorded as a component of accumulated other comprehensive income on the condensed consolidated balance sheet. For the three months ended March 31, 2014 and 2013, comprehensive loss includes foreign currency translation loss of $104,590 and gain of $148,437, respectively and unrealized loss of $2,650 on Geron common shares held by Asterias as of March 31, 2014. The unrealized gain/loss from the Geron shares is a component of comprehensive loss because these shares are considered a marketable equity security that are available for sale. For the three months ended March 31, 2014 and 2013, foreign currency transaction loss, included in other income/(expense), amounted to $10,212 and $21,977, respectively. | ||||
Income taxes – BioTime accounts for income taxes in accordance with GAAP requirements, which prescribe the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect. Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized. The FASB guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. For 2013, Asterias will file separate U.S. federal and state income tax returns but effectively BioTime will combine Asterias’ tax provision with BioTime’s. BioTime recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense, however, no amounts were accrued for the payment of interest and penalties as of March 31, 2014 and 2013 respectively. BioTime files its income tax returns in the U.S. federal and various state and local and foreign jurisdictions. Generally, BioTime is no longer subject to income tax examinations by major taxing authorities for years before 2010. Any potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with U.S. federal, state and local and foreign tax laws. Management does not expect that the total amount of unrecognized tax benefits will materially change over the next nine months. | ||||
A deferred income tax benefit of approximately $1,349,000 was recorded for the three months ended March 31, 2014, of which approximately $1,151,000 was related to federal and $198,000 was related to state taxes. A deferred income tax benefit of approximately $3,280,000 was recorded for the year ended December 31, 2013, of which approximately $2,800,000 was related to federal and $480,000 was related to state taxes. No tax benefit had been recorded through September 30, 2013 because of the net operating losses incurred and a full valuation allowance had been provided. | ||||
Stock-based compensation – BioTime adopted accounting standards governing share-based payments, which require the measurement and recognition of compensation expense for all share-based payment awards made to directors and employees, including employee stock options, based on estimated fair values. In March 2005, the SEC issued additional guidelines which provide supplemental implementation guidance for valuation of share-based payments. BioTime has applied the provisions of this guidance in such valuations as well. Consistent with those guidelines, BioTime utilizes the Black-Scholes Merton option pricing model. BioTime's determination of fair value of share-based payment awards on the date of grant using that option-pricing model is affected by BioTime's stock price as well as by assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, BioTime's expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. The expected term of options granted is derived from historical data on employee exercises and post-vesting employment termination behavior. The risk-free rate is based on the U.S. Treasury rates in effect during the corresponding period of grant. Although the fair value of employee stock options is determined in accordance with recent FASB guidance, changes in the subjective assumptions can materially affect the estimated value. | ||||
Impairment of long-lived assets – BioTime’s long-lived assets, including intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. If an impairment indicator is present, BioTime will evaluate recoverability by a comparison of the carrying amount of the assets to future undiscounted net cash flows expected to be generated by the assets. If the assets are impaired, the impairment recognized is measured by the amount by which the carrying amount exceeds the estimated fair value of the assets. | ||||
Deferred license and consulting fees – Deferred license and consulting fees consist of the value of warrants issued to third parties for services, and deferred license fees paid to acquire rights to use the proprietary technologies of third parties. The value of the warrants is being amortized over the period the services are being provided, and the license fees are being amortized over the estimated useful lives of the licensed technologies or licensed research products. See Note 5. | ||||
Loss per share – Basic net loss per share is computed by dividing net loss attributable to BioTime by the weighted-average number of common shares outstanding for the period. Diluted net loss per share reflects the weighted-average number of common shares outstanding plus the potential effect of dilutive securities or contracts which are convertible to common shares, such as options and warrants (using the treasury stock method) and shares issuable in future periods, except in cases where the effect would be anti-dilutive. Diluted loss per share for the three months ended March 31, 2014, and 2013 excludes any effect from 10,546,137 treasury shares, 5,491,301 options and 9,751,615 warrants and 2,360,968 treasury shares, 4,771,301 options and 816,612 warrants, respectively. | ||||
Fair value of financial instruments – The fair value of BioTime’s assets and liabilities, which qualify as financial instruments under FASB guidance regarding disclosures about fair value of financial instruments, approximate the carrying amounts presented in the accompanying condensed consolidated balance sheets. | ||||
Effect of recently issued and recently adopted accounting pronouncements – There are no recently issued accounting standards which are not yet effective which BioTime believes would materially impact the condensed consolidated financial statements. |
Inventory
Inventory | 3 Months Ended |
Mar. 31, 2014 | |
Inventory [Abstract] | ' |
Inventory | ' |
2. Inventory | |
BioTime held $223,665 and $165,771 of inventory of finished products on-site at its corporate headquarters in Alameda, California at March 31, 2014 and December 31, 2013, respectively. Finished goods products of $12,923 were held by a third party on consignment at March 31, 2014 and December 31, 2013. |
Equipment
Equipment | 3 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Equipment [Abstract] | ' | ||||||||
Equipment | ' | ||||||||
3. Equipment | |||||||||
At March 31, 2014 and December 31, 2013, equipment, furniture and fixtures were comprised of the following: | |||||||||
31-Mar-14 | December 31, | ||||||||
(unaudited) | 2013 | ||||||||
Equipment, furniture and fixtures | $ | 4,645,077 | $ | 4,431,586 | |||||
Accumulated depreciation | (1,685,927 | ) | (1,433,853 | ) | |||||
Equipment, net | $ | 2,959,150 | $ | 2,997,733 | |||||
Depreciation expense amounted to $256,945 and $113,356 for the three months ended March 31, 2014 and 2013, respectively. |
Intangible_assets
Intangible assets | 3 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Intangible assets [Abstract] | ' | ||||||||
Intangible assets | ' | ||||||||
4. Intangible assets | |||||||||
At March 31, 2014 and December 31, 2013, intangible assets and intangible assets net of amortization were comprised of the following: | |||||||||
31-Mar-14 | December 31, | ||||||||
(unaudited) | 2013 | ||||||||
Intangible assets | $ | 54,719,918 | $ | 54,719,918 | |||||
Accumulated amortization | (9,879,831 | ) | (8,511,833 | ) | |||||
Intangible assets, net | $ | 44,840,087 | $ | 46,208,085 | |||||
BioTime amortizes its intangible assets generally over an estimated period of 10 years on a straight line basis. BioTime recognized $1,367,998 and $642,573 in amortization expense of intangible assets during the three months ended March 31, 2014 and 2013, respectively. |
Royalty_Obligation_and_Deferre
Royalty Obligation and Deferred License Fees | 3 Months Ended | ||||
Mar. 31, 2014 | |||||
Royalty Obligation and Deferred License Fees [Abstract] | ' | ||||
Royalty Obligation and Deferred License Fees | ' | ||||
5. Royalty Obligation and Deferred License Fees | |||||
BioTime amortizes deferred license fees over the estimated useful lives of the licensed technologies or licensed research products. BioTime is applying a 10 year estimated useful life to the technologies and products that it is currently licensing. The estimation of the useful life any technology or product involves a significant degree of inherent uncertainty, since the outcome of research and development or the commercial life a new product cannot be known with certainty at the time that the right to use the technology or product is acquired. BioTime will review its amortization schedules for impairments that might occur earlier than the original expected useful lives. | |||||
WARF License—Research Products | |||||
On January 3, 2008, BioTime entered into a Commercial License and Option Agreement with Wisconsin Alumni Research Foundation (“WARF”). The WARF license permits BioTime to use certain patented and patent pending technology belonging to WARF, as well as certain stem cell materials, for research and development purposes, and for the production and marketing of products used as research tools, including in drug discovery and development. BioTime or ReCyte Therapeutics will pay WARF royalties on the sale of products and services using the technology or stem cells licensed from WARF. The royalty will range from 2% to 4%, depending on the kind of products sold. The royalty rate is subject to certain reductions if BioTime also becomes obligated to pay royalties to a third party in order to sell a product. BioTime paid licensing fees, totaling $295,000 in cash and BioTime stock, and reimbursed WARF for certain costs associated with preparing, filing, and maintaining the licensed patents. In addition, BioTime pays WARF $25,000 annually as a license maintenance fee. The licensing fees less the amortized portion were included in deferred license fees in BioTime’s condensed consolidated balance sheet as of March 31, 2014 and December 31, 2013. | |||||
ReCyte Therapeutics Licenses from ACT | |||||
On July 10, 2008, ReCyte Therapeutics entered into a License Agreement with Advanced Cell Technology, Inc. (“ACT”), under which ReCyte Therapeutics acquired exclusive worldwide rights to use ACT’s “ACTCellerate™” technology for methods to accelerate the isolation of novel cell strains from pluripotent stem cells. ReCyte Therapeutics paid ACT a $250,000 license fee. ReCyte Therapeutics has assigned its rights under the License Agreement to BioTime. BioTime will pay an 8% royalty on sales of products, services, and processes that utilize the licensed technology. Once a total of $1,000,000 of royalties has been paid, no further royalties will be due. The license will expire in twenty years or upon the expiration of the last to expire of the licensed patents, whichever is later. The $250,000 license fee less the amortized portion is included in deferred license fees in BioTime’s condensed consolidated balance sheet as of March 31, 2014 and December 31, 2013. | |||||
On August 15, 2008, ReCyte Therapeutics entered into a License Agreement and a Sublicense Agreement with ACT under which ReCyte Therapeutics acquired world-wide rights to use an array of ACT technology (the “ACT License”) and technology licensed by ACT from affiliates of Kirin Pharma Company, Limited (the “Kirin Sublicense”). The ACT License and Kirin Sublicense permit the commercialization of products in human therapeutic and diagnostic product markets. | |||||
The technology licensed by ReCyte Therapeutics covers methods to transform cells of the human body, such as skin cells, into an embryonic state in which the cells will be pluripotent. Under the ACT License, ReCyte Therapeutics paid ACT a $200,000 license fee and will pay a 5% royalty on sales of products, services, and processes that utilize the licensed ACT technology, and 20% of any fees or other payments (other than equity investments, research and development costs, loans and royalties) received by ReCyte Therapeutics from sublicensing the ACT technology to third parties. Once a total of $600,000 of royalties has been paid, no further royalties will be due. The license will expire in twenty years or upon the expiration of the last-to-expire of the licensed patents, whichever is later. The $200,000 license fee payment less the amortized portion is included in deferred license fees in BioTime’s condensed consolidated balance sheet as of March 31, 2014 and December 31, 2013. | |||||
Under the Kirin Sublicense, ReCyte Therapeutics has paid ACT a $50,000 license fee and will pay a 3.5% royalty on sales of products, services, and processes that utilize the licensed ACT technology, and 20% of any fees or other payments (other than equity investments, research and development costs, loans and royalties) received by ReCyte Therapeutics from sublicensing the Kirin Technology to third parties. ReCyte Therapeutics will also pay to ACT or to an affiliate of Kirin Pharma Company, Limited (“Kirin”), annually, the amount, if any, by which royalties payable by ACT under its license agreement with Kirin are less than the $50,000 annual minimum royalty due. Those payments by ReCyte Therapeutics will be credited against other royalties payable to ACT under the Kirin Sublicense. The license will expire upon the expiration of the last to expire of the licensed patents, or May 9, 2016 if no patents are issued. The $50,000 license fee payment less the amortized portion is included in deferred license fees in BioTime’s condensed consolidated balance sheet as of March 31, 2014 and December 31, 2013. | |||||
ReCyte Therapeutics License from RGI | |||||
On February 29, 2009, ReCyte Therapeutics entered into a Stem Cell Agreement with Reproductive Genetics Institute (“RGI”). In partial consideration of the rights and licenses granted to ReCyte Therapeutics by RGI, BioTime issued to RGI 32,259 common shares, having a market value of $50,000 on the effective date of the Stem Cell Agreement. This $50,000 payment less the amortized portion is included in deferred license fees in BioTime’s condensed consolidated balance sheet as of March 31, 2014 and December 31, 2013. | |||||
OncoCyte License from SBMRI | |||||
Through BioTime’s acquisition of the assets of Cell Targeting, Inc. during March 2011, BioTime acquired a royalty-bearing, exclusive, worldwide license from the Sanford-Burnham Medical Research Institute (“SBMRI”) to use certain patents pertaining to homing peptides for preclinical research investigations of cell therapy treatments, and to enhance cell therapy products for the treatment and prevention of disease and injury in conjunction with BioTime’s own proprietary technology or that of a third party. BioTime assigned the SBMRI license to OncoCyte during July 2011. OncoCyte will pay SBMRI a royalty of 4% on the sale of pharmaceutical products, and 10% on the sale of any research-use products that OncoCyte develops using or incorporating the licensed technology; and 20% of any payments OncoCyte receives for sublicensing the patents to third parties. The royalties payable to SBMRI may be reduced by 50% if royalties or other fees must be paid to third parties in connection with the sale of any products. An annual license maintenance fee is payable each year during the term of the license, and after commercial sales of royalty bearing products commence, the annual fee will be credited towards OncoCyte's royalty payment obligations for the applicable year. OncoCyte will reimburse SBMRI for 25% of the costs incurred in filing, prosecuting, and maintaining patent protection, subject to OncoCyte’s approval of the costs. OncoCyte incurred no royalty expenses to date as of March 31, 2014. | |||||
Cell Cure Neurosciences License from Hadasit | |||||
Cell Cure Neurosciences has entered into an Amended and Restated Research and License Agreement with Hadasit Medical Research Services and Development, Ltd. (“Hadasit”) under which Cell Cure Neurosciences received an exclusive license to use certain of Hadasit’s patented technologies for the development and commercialization for hES cell-derived cell replacement therapies for retinal degenerative diseases. Cell Cure Neurosciences paid Hadasit 249,058 New Israeli Shekels as a reimbursement for patent expenses incurred by Hadasit, and pays Hadasit quarterly fees for research and product development services under a related Product Development Agreement. | |||||
If Teva Pharmaceutical Industries Ltd. (“Teva”) exercises its option to license OpRegen® or OpRegen®-Plus under the terms of a Research and Exclusive License Option Agreement (the “Teva License Option Agreement”), Cell Cure Neurosciences will pay Hadasit 30% of all sublicensing payments made by Teva to Cell Cure Neurosciences, other than payments for research, reimbursements of patent expenses, loans or equity investments. | |||||
If Teva does not exercise its option and Cell Cure Neurosciences instead commercializes OpRegen® or OpRegen®-Plus itself or sublicenses the Hadasit patents to a third party for the completion of development or commercialization of OpRegen® or OpRegen®-Plus, Cell Cure Neurosciences will pay Hadasit a 5% royalty on sales of products that utilize the licensed technology. Cell Cure Neurosciences will also pay sublicensing fees ranging from 10% to 30% of any payments Cell Cure Neurosciences receives from sublicensing the Hadasit patents to companies other than Teva. Commencing in January 2017, Hadasit will be entitled to receive an annual minimum royalty payment of $100,000 that will be credited toward the payment of royalties and sublicense fees otherwise payable to Hadasit during the calendar year. If Cell Cure Neurosciences or a sublicensee other than Teva paid royalties during the previous year, Cell Cure Neurosciences may defer making the minimum royalty payment until December and will be obligated to make the minimum annual payment to the extent that royalties and sublicensing fee payments made during that year are less than $100,000. | |||||
If Teva does not exercise its option under the Teva License Option Agreement and instead Cell Cure Neurosciences or a sublicensee other than Teva conducts clinical trials of OpRegen® or OpRegen®-Plus, Hadasit will be entitled to receive certain milestone payments from Cell Cure Neurosciences upon the first attainment of certain clinical trial milestones in the process of seeking regulatory approval to market a product developed by Cell Cure Neurosciences using the licensed patents. Hadasit will receive $250,000 upon the enrollment of patients in the first Phase I clinical trial, $250,000 upon the submission of Phase II clinical trial data to a regulatory agency as part of the approval process, and $1 million upon the enrollment of the first patient in the first Phase III clinical trial. These milestone payments are creditable by Cell Cure Neurosciences against sublicensing receipts that are payable to Hadasit at the time of each milestone payment for said milestone payment, except that the $1 million milestone payment shall only be creditable by Cell Cure Neurosciences if it received the sublicensing receipts in the amount of $50 million. | |||||
BioTime License for the University of Utah | |||||
Through the merger of Glycosan into OrthoCyte during March 2011, BioTime acquired a license from the University of Utah to use certain patents in the production and sale of certain hydrogel products. Under the License Agreement, the scope of which was expanded by an amendment during August 2012, BioTime will pay a 3% royalty on sales of products and services performed that utilize the licensed patents. Commencing in 2014, BioTime will be obligated to pay minimum royalties to the extent that actual royalties on products sales and services utilizing the patents are less than the minimum royalty amount. The minimum royalty amounts are $2,500 in 2014 and $30,000 each year thereafter during the term of the License Agreement. BioTime shall also pay the University of Utah 30% of any sublicense fees or royalties received under any sublicense of the licensed patents. | |||||
BioTime will pay the University of Utah $5,000 upon the issuance of each of the first five licensed patents issued in the U.S., subject to reduction to $2,500 for any patent that the University has licensed to two or more other licensees for different uses. BioTime will also pay a $225,000 milestone fee within six months after the first sale of a “tissue engineered product” that utilizes a licensed patent. A tissue engineered product is defined as living human tissues or cells on a polymer platform, created at a place other than the point-of-care facility, for transplantation into a human patient. | |||||
BioTime License from Cornell University | |||||
On August 23, 2011, BioTime entered into a License Agreement with Cornell University for the worldwide development and commercialization of technology for the differentiation of hES cells into vascular endothelial cells. | |||||
Cornell will be entitled to receive a nominal initial license fee and nominal annual license maintenance fees. The obligation to pay annual license maintenance fees will end when the first human therapeutic products developed under the license is sold. BioTime will pay Cornell a milestone payment upon the achievement of a research product sale milestone amount, and will make milestone payments upon the attainment of certain FDA approval milestones for therapeutic products developed under the license, including (i) the first Phase II clinical trial dosing of a human therapeutic product, (ii) the first Phase III clinical trial dosing of a human therapeutic product; (iii) FDA approval of the first human therapeutic product for age-related vascular disease; and (iv) FDA approval of the first human therapeutic product for cancer. | |||||
BioTime will pay Cornell royalties on the sale of products and services using the license, and will share with Cornell a portion of any cash payments, other than royalties, that BioTime receives for the grant of sublicenses to non-affiliates. The potential royalty percentage rates to be paid to Cornell will be in the low to mid-single digit range depending on the product. BioTime will also reimburse Cornell for costs related to the patent applications and any patents that may issue that are covered by the license. | |||||
In conjunction with the License Agreement, BioTime also entered into a Sponsored Research Agreement under which scientists at Weill Cornell Medical College will engage in certain research for BioTime over a three year period beginning August 2011. | |||||
Asterias License from WARF | |||||
Asterias has entered into a Non-Exclusive License Agreement with WARF under which Asterias was granted a worldwide non-exclusive license under certain WARF patents and WARF-owned embryonic stem cell lines to develop and commercialize therapeutic, diagnostic and research products. The licensed patents include patents covering primate embryonic stem cells as compositions of matter, as well as methods for growth and differentiation of primate embryonic stem cells. The licensed stem cell lines include the H1, H7, H9, H13 and H14 hES cell lines. | |||||
In consideration of the rights licensed, Asterias has agreed to pay WARF an upfront license fee, payments upon the attainment of specified clinical development milestones, royalties on sales of commercialized products, and, subject to certain exclusions, a percentage of any payments that Asterias may receive from any sublicenses that it may grant to use the licensed patents or stem cell lines. | |||||
The license agreement will terminate with respect to licensed patents upon the expiration of the last licensed patent to expire. Asterias may terminate the license agreement at any time by giving WARF prior written notice. WARF may terminate the license agreement if payments of earned royalties, once begun, cease for a specified period of time or if Asterias and any third parties collaborating or cooperating with Asterias in the development of products using the licensed patents or stem cell lines fail to spend a specified minimum amount on research and development of products relating to the licensed patents or stem cell lines for a specified period of time. WARF also has the right to terminate the license agreement if Asterias breaches the license agreement or becomes bankrupt or insolvent or if any of the licensed patents or stem cell lines are offered to creditors. | |||||
Asterias License from the University of California | |||||
Geron assigned to Asterias its Exclusive License Agreement with The Regents of the University of California for patents covering a method for directing the differentiation of multipotential hES cells to glial-restricted progenitor cells that generate pure populations of oligodendrocytes for remyelination and treatment of spinal cord injury. Pursuant to this agreement, Asterias has an exclusive worldwide license under such patents, including the right to grant sublicenses, to create products for biological research, drug screening, and human therapy using the licensed patents. Under the license agreement, Asterias will be obligated to pay the university a royalty of 1% from sales of products that are covered by the licensed patent rights, and a minimum annual royalty of $5,000 starting in the year in which the first sale of a product covered by any licensed patent rights occurs, and continuing for the life of the applicable patent right under the agreement. The royalty payments due are subject to reduction, but not by more than 50%, to the extent of any payments that Asterias may be obligated to pay to a third party for the use of patents or other intellectual property licensed from the third party in order to make, have made, use, sell, or import products or otherwise exercise its rights under the Exclusive License Agreement. Asterias will be obligated to pay the university 7.5% of any proceeds, excluding debt financing and equity investments, and certain reimbursements, that its receives from sublicensees, other than Asterias’ affiliates and joint ventures relating to the development, manufacture, purchase, and sale of products, processes, and services covered by the licensed patent. The license agreement will terminate on the expiration of the last-to-expire of the university's issued licensed patents. If no further patents covered by the license agreement are issued, the license agreement would terminate in 2024. The university may terminate the agreement in the event of Asterias’ breach of the agreement. Asterias can terminate the agreement upon 60 days' notice. | |||||
Asterias Sublicense from Geron | |||||
Asterias has received from Geron an exclusive sublicense under certain patents owned by the University of Colorado’s University License Equity Holdings, Inc. relating to telomerase (the “Telomerase Sublicense”). The Telomerase Sublicense entitles Asterias to use the technology covered by the patents in the development of VAC1 and VAC2 as immunological treatments for cancer. Under the Telomerase Sublicense, Asterias paid Geron a one-time upfront license fee of $65,000, and will pay Geron an annual license maintenance fee of $10,000 due on each anniversary of the effective date of the Telomerase Sublicense, and a 1% royalty on sales of any products that Asterias may develop and commercialize that are covered by the sublicensed patents. The Telomerase Sublicense will expire concurrently with the expiration of Geron’s license. That license will terminate during April 2017 when the licensed patents expire. The Telomerase Sublicense may also be terminated by Asterias by giving Geron 90 days written notice, by Asterias or by Geron if the other party breaches its obligations under the sublicense agreement and fails to cure their breach within the prescribed time period, or by Asterias or by Geron upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors by the other party. See Note 8. | |||||
As of March 31, 2014, future amortization of deferred license fees described above was as follows: | |||||
Year Ended | Deferred License | ||||
December 31, | Fees | ||||
2014 | $ | 83,615 | |||
2015 | 111,000 | ||||
2016 | 111,000 | ||||
2017 | 111,000 | ||||
Thereafter | 111,843 | ||||
Total | $ | 528,458 |
Accounts_Payable_and_Accrued_L
Accounts Payable and Accrued Liabilities | 3 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Accounts Payable and Accrued Liabilities [Abstract] | ' | ||||||||
Accounts Payable and Accrued Liabilities | ' | ||||||||
6. Accounts Payable and Accrued Liabilities | |||||||||
At March 31, 2014 and December 31, 2013, accounts payable and accrued liabilities consisted of the following: | |||||||||
31-Mar-14 | December 31, | ||||||||
(unaudited) | 2013 | ||||||||
Accounts payable | $ | 2,527,330 | $ | 3,887,950 | |||||
Accrued bonuses | 229,905 | 600,000 | |||||||
Other accrued liabilities | 2,685,828 | 2,234,674 | |||||||
$ | 5,443,063 | $ | 6,722,624 |
Equity
Equity | 3 Months Ended |
Mar. 31, 2014 | |
Equity [Abstract] | ' |
Equity | ' |
7. Equity | |
Preferred Shares | |
BioTime is authorized to issue 2,000,000 shares of preferred stock. The preferred shares may be issued in one or more series as the board of directors may by resolution determine. The board of directors is authorized to fix the number of shares of any series of preferred shares and to determine or alter the rights, references, privileges, and restrictions granted to or imposed on the preferred shares as a class, or upon any wholly unissued series of any preferred shares. The board of directors may, by resolution, increase or decrease (but not below the number of shares of such series then outstanding) the number of shares of any series of preferred shares subsequent to the issue of shares of that series. | |
As of March 31, 2014, BioTime has 70,000 outstanding preferred shares. On March 4, 2014, BioTime sold 70,000 shares of a newly authorized Series A Convertible Preferred Stock (“Series A Preferred Stock”) for $3.5 million. The Series A Preferred Stock carries a cumulative annual 3% preferred dividend or $1.50 per share, in preference to BioTime common shares. Each share of Series A Preferred Stock is convertible, at the election of the holder, into BioTime common shares at a conversion price of $4.00 per share, a current conversion ratio of 12.5 common shares for each share of Series A Preferred Stock. | |
In connection with the sale of the Series A Preferred Stock, BioTime also entered into an Option Agreement with each purchaser of Series A Preferred Stock entitling them, for a period of five years, to exchange their shares of Series A Preferred Stock for shares of common stock of BioTime’s subsidiary LifeMap Sciences, Inc. held by BioTime at the ratio of 12.5 shares of LifeMap Sciences common stock for each share of BioTime Series A Preferred Stock. | |
In addition to the preferred dividend, the Series A Preferred Stock will be entitled to participate with BioTime common shares in any dividends or distributions on common shares (other than dividends and distributions of common shares resulting in an adjustment of the conversion price) as if all shares of Series A Preferred Stock were then converted into common shares. | |
All outstanding Series A Preferred Stock will automatically be converted into common shares on March 4, 2019, or if holders of a majority of the outstanding shares of Series A Preferred Stock, voting as a class, approve or consent to a conversion. The conversion price is subject to prorata adjustment in the event of a subdivision or reclassification of the common shares into a greater number of shares, a stock dividend paid in common shares, or a stock combination or reclassification of the common shares into a smaller number of shares. | |
The Series A Preferred Stock will be entitled to vote with common shares on all matters submitted to common shareholders for approval. Each share of Series A Preferred Stock will be entitled to a number of votes equal to the number of common shares into which it could then be converted. The Series A Preferred Stock will also vote as a separate class on certain matters affecting those shares. | |
In the event of a liquidation or dissolution of BioTime, holders of Series A Preferred Stock will be entitled to receive payment of any accrued but unpaid preferred dividends before any assets may be distributed to holders of common shares. After payment of the accrued dividends, the Series A Preferred Stock will participate with the common shares in the distribution of any assets available to shareholders, as if the Series A Preferred Stock was then converted into common shares. | |
Common Shares | |
BioTime is authorized to issue 125,000,000 common shares with no par value. As of March 31, 2014, BioTime had issued 69,617,329 common shares and outstanding 59,071,192 common shares. | |
During the three months ended March 31, 2014 and 2013, BioTime recognized stock-based compensation expenses of $801,554 and $691,946, respectively, due to stock options granted to employees and directors. During the three months ended March 31, 2014 and 2013, BioTime granted 1,205,000 and 1,090,000 options, respectively, under its 2012 Equity Incentive Plan. | |
During the three months ended March 31, 2014, 45,000 options and no warrants were exercised. |
Asset_Contribution_Agreement
Asset Contribution Agreement | 3 Months Ended | ||||
Mar. 31, 2014 | |||||
Asset Contribution Agreement [Abstract] | ' | ||||
Asset Contribution Agreement | ' | ||||
8. Asset Contribution Agreement | |||||
On January 4, 2013, BioTime and Asterias entered into an Asset Contribution Agreement with Geron Corporation (“Geron”) pursuant to which BioTime and Geron agreed to concurrently contribute certain assets to Asterias in exchange for shares of Asterias common stock. The transaction closed on October 1, 2013. | |||||
Transfer of BioTime Assets | |||||
Under the Asset Contribution Agreement, BioTime contributed to Asterias 8,902,077 BioTime common shares registered for re-sale under the Securities Act of 1933, as amended, warrants to subscribe for and purchase 8,000,000 additional BioTime common shares (the “BioTime Warrants”) exercisable for a period of five years at a price of $5.00 per share, subject to pro rata adjustment for certain stock splits, reverse stock splits, stock dividends, recapitalizations and other transactions; a 10% common stock interest in BioTime’s subsidiary OrthoCyte; a 6% ordinary share interest in BioTime’s subsidiary Cell Cure Neurosciences; and a quantity of certain hES cell lines produced under “good manufacturing practices” sufficient to generate master cell banks, and non-exclusive, world-wide, royalty-free licenses to use those cell lines and certain patents pertaining to stem cell differentiation technology for any and all purposes. In return, Asterias issued to BioTime 21,773,340 shares of its Series B common stock, par value $0.0001 per share (“Series B Shares”), and warrants to purchase 3,150,000 Series B Shares, exercisable for a period of three years from the date of issue at an exercise price of $5.00 per share. In addition, BioTime cancelled Asterias’ obligations to repay the principal amount of a loan in the amount of $5,000,000 arising from cash financing provided to Asterias by BioTime during 2013 prior to the closing of the asset contribution transaction under the Asset Contribution Agreement. | |||||
Because Asterias is a subsidiary of BioTime, the transfer of assets from BioTime was accounted for as a transaction under common control. Non-monetary assets received by Asterias were recorded at their historical cost basis amounts with BioTime. Monetary assets were recorded at fair value. The difference between the value of assets contributed by BioTime and the fair value of consideration issued to BioTime was recorded as an additional contribution by BioTime, in additional paid-in capital. | |||||
The assets transferred by BioTime and the related consideration paid were recorded as follows: | |||||
Consideration transferred to BioTime: | |||||
Asterias Series B shares | $ | 52,164,568 | |||
Warrants to purchase Asterias Series B shares | 2,012,481 | ||||
Excess of contributed assets’ value over consideration | 4,800,063 | ||||
Total consideration issued | $ | 58,977,112 | |||
Assets transferred by BioTime: | |||||
BioTime common shares, at fair value | $ | 34,985,163 | |||
BioTime Warrants, at fair value | 18,276,406 | ||||
Cancellation of outstanding obligation to BioTime | 5,000,000 | ||||
Investment in affiliates, at cost | 415,543 | ||||
Geron asset acquisition related transaction costs paid by BioTime | 300,000 | ||||
Total assets transferred | $ | 58,977,112 | |||
The fair value of the Asterias Series B shares issued was estimated at $2.40 based on the Asterias enterprise value as determined on January 4, 2013, at the time the Asset Contribution Agreement was negotiated and executed by its parties, and as adjusted for subsequent changes in fair values of assets the parties agreed to contribute. The fair value of the warrants to purchase Asterias Series B shares was computed using a Black Scholes Merton option pricing model, which utilized the following assumptions: expected term equal to the contractual term of three years, which is equal to the contractual life of the warrants; risk-free rate of 0.63%; 0% expected dividend yield; 69.62% expected volatility based on the average historical common stock volatility of BioTime and Geron, which were used as Asterias’ common stock does not have a trading history; a stock price of $2.40; and an exercise price of $5.00. | |||||
BioTime common shares were valued at $3.93 using the closing price per BioTime common shares on the NYSE MKT on October 1, 2013. The fair value of the BioTime Warrants was computed using a Black Scholes Merton option pricing model, which utilized the following assumptions: expected term equal to the contractual term of five years, which is equal to the contractual life of the warrants; risk-free rate of 1.42%; 0% expected dividend yield; 77.63% expected volatility based on historical common stock volatility of BioTime; a stock price of $3.93; and an exercise price of $5.00. | |||||
The investment in OrthoCyte and Cell Cure Neurosciences stock represents a non-monetary asset and was recorded at BioTime’s historical cost because BioTime is a common parent to Asterias and those two BioTime subsidiaries. | |||||
Geron Assets Acquisition | |||||
Under the Asset Contribution Agreement, Geron contributed to Asterias certain patents, patent applications, trade secrets, know-how and other intellectual property rights with respect to the technology of Geron directly related to the research, development and commercialization of certain products and know-how related to hES cells; certain biological materials, reagents, laboratory equipment; as well as clinical trial documentation, files and data, primarily related to GRNOPC1 clinical trials for spinal cord injury and VAC1 clinical trials for acute myelogenous leukemia. Asterias assumed all obligations related to such assets that would be attributable to periods, events or circumstances after the Asset Contribution Agreement closing date, including those related to an appeal filed in the United States District Court in Civil Action No. C12-04813 (the “ViaCyte Appeal”) seeking the reversal of two adverse determinations by the United States Patent and Trademark Office’s Board of Patent Appeals and Interferences with respect to two patent applications in U.S. Patent Interference 105,734, involving US patent 7,510,876 (ViaCyte) and US patent application 11/960,477 (Geron), and U.S. Patent Interference 105,827 involving US patent 7,510,876 (ViaCyte) and US patent application 12/543,875 (Geron). Asterias also assumed the patent interferences upon which the ViaCyte Appeal is based, as well as certain oppositions filed by Geron against certain ViaCyte, Inc. patent filings in Australia and in the European Patent Office. | |||||
As consideration for the acquisition of assets from Geron, Asterias issued to Geron 6,537,779 shares of Series A common stock, par value $0.0001 per share (“Series A Shares”), which Geron had agreed to distribute to its stockholders, on a pro rata basis, subject to applicable legal requirements and certain other limitations (the “Series A Distribution”). Asterias is also obligated to distribute to the holders of its Series A Shares the 8,000,000 shares of BioTime Warrants contributed to Asterias by BioTime. Asterias will distribute the BioTime Warrants as promptly as practicable after notice from Geron that the Series A Distribution has been completed. | |||||
In addition, Asterias agreed to bear certain transaction costs in connection with the Geron asset acquisition. Such transaction costs were allocated to acquisition of assets in the amount of $1,519,904 and issuance of equity in the amount of $541,800. | |||||
The assets contributed to Asterias by Geron did not include workforce or any processes to be applied to the patents, biological materials, and other assets acquired, and therefore did not constitute a business. Accordingly, the acquisition of the Geron assets has been accounted for as an acquisition of assets in accordance with the relevant provisions of Accounting Standards Codification (ASC) 805-50. Total consideration payable by Asterias, including transaction costs, has been allocated to the assets acquired based on relative fair values of those assets as of the date of the transaction, October 1, 2013, in accordance with ASC 820, Fair Value Measurement. | |||||
The assets acquired from Geron and the related consideration were recorded as follows: | |||||
Consideration paid to Geron: | |||||
Asterias Series A shares, net of share issuance costs of $541,800 | $ | 15,121,222 | |||
Obligation to distribute BioTime Warrants | 18,276,406 | ||||
Transaction and other costs | 1,519,904 | ||||
Total consideration paid | $ | 34,917,532 | |||
Assets acquired from Geron (preliminary allocation): | |||||
Patents and other intellectual property rights related to hES cells | $ | 29,017,009 | |||
Deferred tax liability arising from difference in book versus tax basis on Geron intangible assets acquired | (11,558,243 | ) | |||
IPR&D expensed upon acquisition | 17,458,766 | ||||
Total assets and in-process research and development acquired | $ | 34,917,532 | |||
The fair value of the Asterias Series A shares issued was estimated at $2.40 based on the estimated Asterias enterprise value as determined by parties at the time the Asset Contribution Agreement was negotiated and executed by its parties on January 4, 2013, as adjusted for subsequent changes in fair values of assets the parties agreed to contribute. | |||||
The fair value of the obligation to distribute BioTime Warrants equals the fair value of such warrants, which was computed as noted above under “Transfer of BioTime Assets.” Because the fair value of the BioTime Warrants is expected to always be equal to the fair value of the obligation to distribute them at any date on which those values are determined, the remeasurement of those values will not result in a charge or credit on the statement of operations. | |||||
The difference between the fair value of assets contributed by Geron and the fair value of consideration issued to Geron was recorded as an additional contribution by Geron, in additional paid-in capital, because the fair value of the assets transferred by Geron was more reliably determined. | |||||
Assets acquired from Geron consist primarily of patents and other intellectual property rights related to hES cells which Asterias intends to license to various parties interested in research, development and commercialization of hES cells technologies, and IPR&D, which includes biological materials, reagents, clinical trial documentation, files and data related primarily to certain clinical trials previously conducted by Geron, which Geron discontinued in November 2011. | |||||
Intangible assets related to IPR&D represent the value of incomplete research and development projects which the company intends to continue. In accordance with the accounting rules in ASC 805, such assets, when acquired in conjunction with acquisition of a business, are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts and are capitalized as an asset. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. However, when acquired in conjunction with an acquisition of assets that do not constitute a business (such as the acquisition of assets from Geron), in accordance with the accounting rules in ASC 805-50, such intangible assets related to IPR&D are expensed upon acquisition. | |||||
The values of the acquired assets were estimated at October 1, 2013 based upon a preliminary review of those assets which took into account factors such as the condition of the cells, cell lines and other biological materials being contributed, the stage of development of particular technology and product candidates related to patents, patent applications, and know-how, the intended use of these assets and the priority assigned to the development of product candidates to which those assets relate, and the assessment of the estimated useful lives of patents. The amounts allocated to patents and other intellectual property rights that Asterias intends to license were capitalized as intangible assets and are being amortized over an estimated useful life period of 10 years. The amounts allocated to IPR&D were expensed at the time of acquisition of the related assets in accordance with the requirements of ASC 805-50. The allocation was based on the relative fair value of assets eligible for capitalization and the fair value of assets representing IPR&D before assessing the deferred tax liability arising from the difference in book versus tax basis on Geron intangible assets acquired, which management estimated to be approximately equal. Accordingly, $17,458,766 was capitalized as of December 31, 2013, and $17,458,766 was expensed. These amounts are preliminary as management has not yet completed a detailed assessment and valuation of the acquired assets. Such assessment and valuation is expected to be completed during the quarter ending June 30, 2014. Accordingly, the amounts included in capitalized intangible assets and expensed IPR&D as of December 31, 2013 are subject to adjustments which could be material. | |||||
Asterias is also obligated to pay Geron royalties on the sale of products, if any, that are commercialized in reliance upon patents acquired from Geron, at the rate of 4% of net sales. | |||||
Stock and Warrant Purchase Agreement with Romulus | |||||
On January 4, 2013, in connection with entering into the Asset Contribution Agreement, Asterias entered into a Stock and Warrant Purchase Agreement with Romulus Films, Ltd (“Romulus”) pursuant to which Romulus agreed to purchase 2,136,000 Series B Shares and warrants to purchase 350,000 additional Series B Shares for $5,000,000 in cash upon the consummation of the acquisition of assets under the Asset Contribution Agreement. On October 1, 2013, the shares and warrants were issued in exchange for $5,000,000 in cash. |
Unaudited_Pro_Forma_Interim_Fi
Unaudited Pro Forma Interim Financial Information - Three Months Ended March 31, 2014 and 2013 | 3 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Unaudited Pro Forma Interim Financial Information - Three Months Ended March 31, 2014 and 2013 [Abstract] | ' | ||||||||
Unaudited Pro Forma Interim Financial Information - Three Months Ended March 31, 2014 and 2013 | ' | ||||||||
9. Unaudited Pro Forma Interim Financial Information – Three Months Ended March 31, 2014 and 2013 | |||||||||
The following unaudited pro forma information gives effect to the asset acquisition through the Asset Contribution Agreement with Geron as if the transaction took place on January 1, 2013. The pro forma information does not necessarily reflect the results of operations that would have occurred had the entities been a single company during the periods presented. | |||||||||
Three Months Ended March 31, | |||||||||
2014 | 2013 | ||||||||
(Unaudited) | (Unaudited) | ||||||||
Revenues, net | $ | 934,721 | $ | 493,705 | |||||
Net loss available to common shareholders | $ | (8,099,014 | ) | $ | (22,572,852 | ) | |||
Net loss per common share – basic and diluted | $ | (0.14 | ) | $ | (0.38 | ) |
Subsequent_Events
Subsequent Events | 3 Months Ended |
Mar. 31, 2014 | |
Subsequent Events [Abstract] | ' |
Subsequent Events | ' |
10. Subsequent Events | |
In May 2014, BioTime raised $6,380,640 of additional equity capital through the sales of BioTime common shares in “at-the-market” transactions through Cantor Fitzgerald & Co., as BioTime's sales agent. | |
On May 5, 2014, BioTime was awarded an SBIR Phase 1 Small Business Grant in the amount of $224,911 from the National Institute of General Medical Sciences (NIGMS) at the National Institutes of Health (NIH). Under this grant entitled “Cell Targeting Peptides for Isolating Patient Specific Stem Cells” BioTime will work on streamlining PureStem® cell line development and developing improved assays for monitoring stem cell differentiation. | |
LifeMap Solutions, Inc.—Mobile Health Software Products | |
On May 6, 2014, LifeMap Solutions, Inc. (“Solutions”), a newly formed subsidiary of LifeMap Sciences, entered into a Co-Development and Option Agreement (the “Agreement”) with the Icahn School of Medicine at Mount Sinai, a nonprofit education corporation (“Mt Sinai”), pursuant to which Solutions and Mt Sinai have agreed to work cooperatively to develop internet, web-based, mobile user or consumer software products to provide users with information that may potentially aid them in improving lifestyle and healthcare decisions and outcomes. | |
Solutions and Mt Sinai will license to each other, on a non-exclusive, royalty free basis, certain “background” intellectual property for joint use in product development. Solutions will pay Mt Sinai for the use of Mt Sinai personnel based on their direct salaries plus an overhead charge, but Mt Sinai has agreed to waive collection of the first $1,000,000 of overhead charges. | |
Solutions will have an option to acquire a world-wide license to use Mt Sinai’s background intellectual property and other intellectual property developed by Mt Sinai alone or jointly with Solutions in the joint development project for the purpose of developing and commercializing the product. The terms of the license agreement that will be executed if Solutions exercises its option under the Agreement (the “License Agreement”) are subject to negotiation by the parties, but will include certain provisions specified in the Agreement, including the obligation of Solutions to pay Mt Sinai: (a) royalties on net sales, (b) a percentage of any consideration received by Solutions from its sublicensees and distributors of the product; (c) all reasonable patent and licensing costs incurred prior to the effective date of the definitive License Agreement in connection with the licensed patent rights and certain other Mount Sinai technology and background intellectual property, and all reasonable attorney’s fees, expenses, official fees, and other charges incident to the preparation, prosecution, and maintenance of licensed patent rights: and (d) up to 5% of the then current equity value of Solutions at the time of a “Significant Transaction.” The percentage to be paid is subject to dilution based on future investment in Solutions and the amount of personnel cost overhead charges waived by Mt Sinai under the Agreement. The term “Significant Transaction” will mean the first to occur of a single transaction, or series of related transactions, consisting of or resulting in any of the following: (i) an assignment, other than to LifeMap Sciences, of the definitive license agreement; (ii) an initial public offering of securities by Solutions (or its successor) or other transaction resulting in any of Solutions’ securities being traded on a nationally recognized stock exchange or automated quotation system; (iii) a sale, license or other disposition of all or substantially all of Solutions’ assets; or (iv) a reorganization, consolidation or merger of Solutions, or sale or transfer of the securities of Solutions, where the holders of Solutions’ outstanding voting securities before the transaction beneficially own less than fifty percent (50%) of the outstanding voting securities, or hold less than fifty percent (50%) of the voting power of the voting security holders of the surviving entity after the transaction. A Significant Transaction shall not be deemed to occur as a result of a bona fide, arm’s-length equity financing for cash in which Solutions issues securities (other than through an initial public offering described in clause (ii) above) representing more than fifty percent (50%) of the voting power of its security holders to venture capital or other similar professional investors who do not actively manage day-to-day operations of Solutions. | |
LifeMap Sciences Stock Purchase Agreement | |
Also on May 6, 2014, BioTime entered into a Stock Purchase Agreement with LifeMap Sciences to provide financing for Solutions’ product development costs under the Agreement with Mt Sinai. BioTime will purchase 2,500,000 shares of LifeMap Sciences common stock for $5,000,000 in four tranches during 2014. LifeMap Sciences will use the proceeds from the sale to provide capital to Solutions. | |
BioTime will also have an option to purchase up to an additional 9,500,000 shares of LifeMap Sciences common stock for $2.00 per share in two tranches related to the attainment of certain product development milestones by Solutions. If BioTime exercises its option it may pay for those LifeMap Sciences shares in up to three installments for each tranche, in cash or in BioTime common shares at the then current market value determined as of the date the option is exercised based on the average closing price of BioTime common shares on the NYSE MKT for the preceding 20 trading days. The number of shares of LifeMap Sciences common stock that BioTime may purchase will be reduced to the extent that LifeMap Sciences raises capital from other sources for product development under the Agreement with Mt Sinai. | |
These condensed consolidated financial statements were approved by management and the Board of Directors, and were issued on May 12, 2014 (unaudited). Subsequent events have been evaluated through that date. |
Organization_Basis_of_Presenta1
Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies (Policies) | 3 Months Ended | |||
Mar. 31, 2014 | ||||
Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies [Abstract] | ' | |||
General | ' | |||
General – BioTime is a biotechnology company engaged in two areas of biomedical research and product development. BioTime's primary focus is in the field of regenerative medicine; specifically human embryonic stem (“hES”) cell and induced pluripotent stem (“iPS”) cell technology. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. BioTime and its subsidiaries plan to develop stem cell products for research and therapeutic use. Asterias Biotherapeutics, Inc. (“Asterias”) acquired the stem cell assets of Geron Corporation (“Geron”) that had been used in Geron’s hES cell research and development programs for the development of products for human therapeutics in the following fields: neurology, oncology, orthopedics, and heart failure and myocardial infarction. OncoCyte Corporation (“OncoCyte”) is developing products and technologies to diagnose cancer. ES Cell International Pte Ltd. (“ESI”), a Singapore private limited company, and BioTime’s ESI BIO division are marketing hES cell lines and stem cell related research products in domestic and over-seas markets. OrthoCyte Corporation (“OrthoCyte”) is developing therapies to treat orthopedic disorders, diseases and injuries. ReCyte Therapeutics, Inc. (“ReCyte Therapeutics”) is developing therapies to treat a variety of cardiovascular and related ischemic disorders, as well as products for research using cell reprogramming technology. Cell Cure Neurosciences Ltd. (“Cell Cure Neurosciences”) is an Israel-based biotechnology company focused on developing stem cell-based therapies for retinal and neurological disorders, including the development of retinal pigment epithelial cells for the treatment of macular degeneration, and treatments for multiple sclerosis. LifeMap Sciences, Inc. (“LifeMap Sciences”) markets, sells and distributes GeneCards®, the leading human gene database and an integrated database suite that includes GeneCards®, the LifeMap Discovery® database of embryonic development, stem cell research and regenerative medicine, and MalaCards, the human disease database. | ||||
BioTime is focusing a portion of its efforts in the field of regenerative medicine on the development and sale of advanced human stem cell products and technologies that can be used by researchers at universities and other institutions, at companies in the bioscience and biopharmaceutical industries, and at other companies that provide research products to companies in those industries. Products for the research market generally can be sold without regulatory (FDA) approval, and are therefore relatively near-term business opportunities when compared to therapeutic products. | ||||
BioTime previously developed blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment and other applications. BioTime’s operating revenues are now derived primarily from licensing fees and advertising from the marketing of the LifeMap Sciences database products, from royalties and licensing fees related to the sale of its plasma volume expander product, Hextend®, from the sale of products for research, and from research grants. | ||||
The unaudited condensed consolidated interim balance sheet as of March 31, 2014, the unaudited condensed consolidated interim statements of operations and comprehensive loss for the three months ended March 31, 2014 and 2013, and the unaudited condensed consolidated interim statements of cash flows for the three months ended March 31, 2014 and 2013 have been prepared by BioTime’s management in accordance with the instructions from Form 10-Q and Regulation S-X. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at March 31, 2014 have been made. The consolidated balance sheet as of December 31, 2013 is derived from the Company’s annual audited financial statements as of that date. The results of operations for the three months ended March 31, 2014 are not necessarily indicative of the operating results anticipated for the full year of 2014. | ||||
Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted as permitted by regulations of the Securities and Exchange Commission (“SEC”) except for the consolidated balance sheet as of December 31, 2013, which was derived from audited financial statements. Certain previously furnished amounts have been reclassified to conform with presentations made during the current periods. It is suggested that these condensed consolidated interim financial statements be read in conjunction with the annual audited consolidated financial statements and notes thereto included in BioTime’s Form 10-K for the year ended December 31, 2013. | ||||
Principles of consolidation | ' | |||
Principles of consolidation – BioTime’s consolidated financial statements include the accounts of its subsidiaries. The following table reflects BioTime’s ownership, directly or through one or more subsidiaries, of the outstanding shares of its subsidiaries. | ||||
BioTime | ||||
Subsidiary | Field of Business | Ownership | Country | |
Asterias Biotherapeutics, Inc. | Research, development and commercialization of human therapeutic products from stem cells potentially in the fields of neurology, oncology, orthopedics, and cardiology | 71.60% | USA | |
ES Cell International Pte Ltd | Stem cell products for research, including clinical grade cell lines | 100% | Singapore | |
produced under cGMP | ||||
OncoCyte Corporation | Cancer diagnostics | 75.30% | USA | |
OrthoCyte Corporation | Orthopedic diseases, including chronic back pain and osteoarthritis | 100% | USA | |
Cell Cure Neurosciences Ltd. | Age-related macular degeneration | 62.50% | Israel | |
Multiple sclerosis | ||||
Parkinson’s disease | ||||
ReCyte Therapeutics, Inc. | Vascular disorders, including cardiovascular-related diseases, ischemic conditions, vascular injuries | 94.80% | USA | |
Stem cell-derived endothelial and cardiovascular related progenitor cells for research, drug testing, and therapeutics | ||||
BioTime Asia, Limited | Stem cell products for research | 81% | Hong Kong | |
LifeMap Sciences, Inc. | Genetic, disease, and stem cell databases | 73.20% | USA | |
LifeMap Sciences, Ltd. | Stem cell database | -1 | Israel | |
LifeMap Solutions, Inc. | Mobile health software | -1 | USA | |
-1 | LifeMap Sciences, Ltd. and LifeMap Solutions, Inc. are wholly-owned subsidiaries of LifeMap Sciences, Inc. | |||
All material intercompany accounts and transactions have been eliminated in consolidation. The consolidated financial statements are presented in accordance with accounting principles generally accepted in the U.S. (“GAAP”) and with the accounting and reporting requirements of SEC Regulation S-X. As of March 31, 2014, BioTime consolidated Asterias, ReCyte Therapeutics, OncoCyte, OrthoCyte, ESI, Cell Cure Neurosciences, BioTime Asia, Limited (“BioTime Asia”), LifeMap Sciences, and LifeMap Sciences, Ltd. as BioTime has the ability to control their operating and financial decisions and policies through its ownership, and the noncontrolling interest is reflected as a separate element of equity on BioTime’s condensed consolidated balance sheets. | ||||
Certain significant risks and uncertainties | ' | |||
Certain significant risks and uncertainties – The operations of BioTime and its subsidiaries are subject to a number of factors that can affect their operating results and financial condition. Such factors include but are not limited to, the following: the results of clinical trials of their respective therapeutic product and medical device candidates; their ability to obtain FDA and foreign regulatory approval to market their respective therapeutic and medical device product candidates; their ability to develop new stem cell research products and technologies; competition from products manufactured and sold or being developed by other companies; the price and demand for their products; their ability to obtain additional financing and the terms of any such financing that may be obtained; their ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products; the availability of ingredients used in their products; and the availability of reimbursement for the cost of their therapeutic products and medical devices (and related treatment) from government health administration authorities, private health coverage insurers, and other organizations. | ||||
Use of estimates | ' | |||
Use of estimates – The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. | ||||
Revenue recognition | ' | |||
Revenue recognition – BioTime complies with SEC Staff Accounting Bulletin guidance on revenue recognition. Royalty revenues consist of product royalty payments. License fee revenues consist primarily of subscription and advertising revenue from our online databases which are recognized based upon respective subscription or advertising periods. Other license fees under certain license agreements were recognized during prior periods when earned and reasonably estimable. Royalties consist primarily of royalties earned on sales of Hextend® and are recognized as revenue in the quarter in which the royalty reports are received from the licensee, rather than the quarter in which the sales took place. When BioTime is entitled to receive up-front nonrefundable licensing or similar fees pursuant to agreements under which BioTime has no continuing performance obligations, the fees are recognized as revenues when collection is reasonably assured. When BioTime receives up-front nonrefundable licensing or similar fees pursuant to agreements under which BioTime does have continuing performance obligations, the fees are deferred and amortized ratably over the performance period. If the performance period cannot be reasonably estimated, BioTime amortizes nonrefundable fees over the life of the contract until such time that the performance period can be more reasonably estimated. Milestone payments, if any, related to scientific or technical achievements are recognized in income when the milestone is accomplished if (a) substantive effort was required to achieve the milestone, (b) the amount of the milestone payment appears reasonably commensurate with the effort expended, and (c) collection of the payment is reasonably assured. Grant income and the sale of research products are recognized as revenue when earned. Revenues from the sale of research products are primarily derived from the sale of hydrogels and stem cell products. | ||||
Cash and cash equivalents | ' | |||
Cash and cash equivalents – BioTime considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. | ||||
Accounts receivable and allowance for doubtful accounts | ' | |||
Accounts receivable and allowance for doubtful accounts – Total trade receivables amounted to approximately $600,400 and $575,900 and grants receivable amounted to approximately $334,700 and $539,300 as of March 31, 2014 and December 31, 2013, respectively. Some of these amounts are deemed uncollectible; as such BioTime recognized allowance for doubtful accounts of approximately $116,800 as of March 31, 2014 and December 31, 2013. BioTime evaluates the collectability of its receivables based on a variety of factors, including the length of time receivables are past due and significant one-time events and historical experience. An additional reserve for individual accounts will be recorded if BioTime becomes aware of a customer’s inability to meet its financial obligations, such as in the case of bankruptcy filings or deterioration in the customer’s operating results or financial position. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted. | ||||
Concentrations of credit risk | ' | |||
Concentrations of credit risk – Financial instruments that potentially subject BioTime to significant concentrations of credit risk consist primarily of cash and cash equivalents. BioTime limits the amount of credit exposure of cash balances by maintaining its accounts in high credit quality financial institutions. Cash equivalent deposits with financial institutions may occasionally exceed the limits of insurance on bank deposits; however, BioTime has not experienced any losses on such accounts. | ||||
Inventory | ' | |||
Inventory – Inventories are stated at the lower of cost or market. Cost, which includes amounts related to materials, labor, and overhead, is determined in a manner which approximates the first-in, first-out (“FIFO”) method. | ||||
Equipment | ' | |||
Equipment – Equipment is stated at cost. Equipment is being depreciated using the straight-line method over a period of 36 to 120 months. See Note 3. | ||||
Intangible assets | ' | |||
Intangible assets – Intangible assets with finite useful lives are amortized over estimated useful lives and intangible assets with indefinite lives are not amortized but rather are tested at least annually for impairment. Acquired in-process research and development intangible assets are accounted for depending on whether they were acquired as part of an acquisition of a business, or as assets that do not constitute a business. When acquired in conjunction with acquisition of a business, these assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts and are capitalized as an asset. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. However, when acquired in conjunction with an acquisition of assets that do not constitute a business (such as the acquisition of assets from Geron), in accordance with the accounting rules in ASC 805-50, such intangible assets related to in-process research and development (“IPR&D”) are expensed upon acquisition. See Note 8. | ||||
Treasury stock | ' | |||
Treasury stock – BioTime accounts for BioTime common shares issued to subsidiaries for future potential working capital needs as treasury stock on the consolidated balance sheet. BioTime has the intent and ability to register any unregistered shares to support the marketability of the shares. | ||||
Warrants to purchase common stock | ' | |||
Warrants to purchase common stock – BioTime generally accounts for warrants issued in connection with equity financings as a component of equity. None of the warrants issued by BioTime as of March 31, 2014 include a conditional obligation to issue a variable number of shares; nor was there a deemed possibility that BioTime may need to settle the warrants in cash. If BioTime were to issue warrants with a conditional obligation to issue a variable number of shares or with the deemed possibility of a cash settlement, BioTime would record the fair value of the warrants as a liability at each balance sheet date and record changes in fair value in other income and expense in the consolidated statements of operations. | ||||
Cost of sales | ' | |||
Cost of sales – BioTime accounts for the cost of research products acquired for sale and any royalties paid as a result of any revenues in accordance with the terms of the respective licensing agreements as cost of sales on the condensed consolidated statement of operations. | ||||
Patent costs | ' | |||
Patent costs – Costs associated with obtaining patents on products or technology developed are expensed as general and administrative expenses when incurred. This accounting is in compliance with guidance promulgated by the Financial Accounting Standards Board (the “FASB”) regarding goodwill and other intangible assets. | ||||
Reclassification | ' | |||
Reclassification – Certain prior year amounts have been reclassified to conform to the current year presentation. Trade and grant receivables are now presented in a separate row from prepaid expenses and other current assets. Additionally, we have carved out the loss on sale of fixed assets amount from other expenses. | ||||
Research and development | ' | |||
Research and development – BioTime complies with FASB requirements governing accounting for research and development costs. Research and development costs are expensed when incurred, and consist principally of salaries, payroll taxes, consulting fees, research and laboratory fees, rent of research facilities, and license fees paid to third parties to acquire patents or licenses to use patents and other technology. | ||||
Foreign currency translation gain/loss and Comprehensive net loss | ' | |||
Foreign currency translation gain and Comprehensive loss – In countries in which BioTime operates, and the functional currency is other than the U.S. dollar, assets and liabilities are translated using published exchange rates in effect at the condensed consolidated balance sheet date. Revenues and expenses and cash flows are translated using an approximate weighted average exchange rate for the period. Resulting translation adjustments are recorded as a component of accumulated other comprehensive income on the condensed consolidated balance sheet. For the three months ended March 31, 2014 and 2013, comprehensive loss includes foreign currency translation loss of $104,590 and gain of $148,437, respectively and unrealized loss of $2,650 on Geron common shares held by Asterias as of March 31, 2014. The unrealized gain/loss from the Geron shares is a component of comprehensive loss because these shares are considered a marketable equity security that are available for sale. For the three months ended March 31, 2014 and 2013, foreign currency transaction loss, included in other income/(expense), amounted to $10,212 and $21,977, respectively. | ||||
Income taxes | ' | |||
Income taxes – BioTime accounts for income taxes in accordance with GAAP requirements, which prescribe the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect. Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized. The FASB guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. For 2013, Asterias will file separate U.S. federal and state income tax returns but effectively BioTime will combine Asterias’ tax provision with BioTime’s. BioTime recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense, however, no amounts were accrued for the payment of interest and penalties as of March 31, 2014 and 2013 respectively. BioTime files its income tax returns in the U.S. federal and various state and local and foreign jurisdictions. Generally, BioTime is no longer subject to income tax examinations by major taxing authorities for years before 2010. Any potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with U.S. federal, state and local and foreign tax laws. Management does not expect that the total amount of unrecognized tax benefits will materially change over the next nine months. | ||||
A deferred income tax benefit of approximately $1,349,000 was recorded for the three months ended March 31, 2014, of which approximately $1,151,000 was related to federal and $198,000 was related to state taxes. A deferred income tax benefit of approximately $3,280,000 was recorded for the year ended December 31, 2013, of which approximately $2,800,000 was related to federal and $480,000 was related to state taxes. No tax benefit had been recorded through September 30, 2013 because of the net operating losses incurred and a full valuation allowance had been provided. | ||||
Stock-based compensation | ' | |||
Stock-based compensation – BioTime adopted accounting standards governing share-based payments, which require the measurement and recognition of compensation expense for all share-based payment awards made to directors and employees, including employee stock options, based on estimated fair values. In March 2005, the SEC issued additional guidelines which provide supplemental implementation guidance for valuation of share-based payments. BioTime has applied the provisions of this guidance in such valuations as well. Consistent with those guidelines, BioTime utilizes the Black-Scholes Merton option pricing model. BioTime's determination of fair value of share-based payment awards on the date of grant using that option-pricing model is affected by BioTime's stock price as well as by assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, BioTime's expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. The expected term of options granted is derived from historical data on employee exercises and post-vesting employment termination behavior. The risk-free rate is based on the U.S. Treasury rates in effect during the corresponding period of grant. Although the fair value of employee stock options is determined in accordance with recent FASB guidance, changes in the subjective assumptions can materially affect the estimated value. | ||||
Impairment of long-lived assets | ' | |||
Impairment of long-lived assets – BioTime’s long-lived assets, including intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. If an impairment indicator is present, BioTime will evaluate recoverability by a comparison of the carrying amount of the assets to future undiscounted net cash flows expected to be generated by the assets. If the assets are impaired, the impairment recognized is measured by the amount by which the carrying amount exceeds the estimated fair value of the assets. | ||||
Deferred license and consulting fees | ' | |||
Deferred license and consulting fees – Deferred license and consulting fees consist of the value of warrants issued to third parties for services, and deferred license fees paid to acquire rights to use the proprietary technologies of third parties. The value of the warrants is being amortized over the period the services are being provided, and the license fees are being amortized over the estimated useful lives of the licensed technologies or licensed research products. See Note 5. | ||||
Loss per share | ' | |||
Loss per share – Basic net loss per share is computed by dividing net loss attributable to BioTime by the weighted-average number of common shares outstanding for the period. Diluted net loss per share reflects the weighted-average number of common shares outstanding plus the potential effect of dilutive securities or contracts which are convertible to common shares, such as options and warrants (using the treasury stock method) and shares issuable in future periods, except in cases where the effect would be anti-dilutive. Diluted loss per share for the three months ended March 31, 2014, and 2013 excludes any effect from 10,546,137 treasury shares, 5,491,301 options and 9,751,615 warrants and 2,360,968 treasury shares, 4,771,301 options and 816,612 warrants, respectively. | ||||
Fair value of financial instruments | ' | |||
Fair value of financial instruments – The fair value of BioTime’s assets and liabilities, which qualify as financial instruments under FASB guidance regarding disclosures about fair value of financial instruments, approximate the carrying amounts presented in the accompanying condensed consolidated balance sheets. | ||||
Effect of recently issued and recently adopted accounting pronouncements | ' | |||
Effect of recently issued and recently adopted accounting pronouncements – There are no recently issued accounting standards which are not yet effective which BioTime believes would materially impact the condensed consolidated financial statements. |
Organization_Basis_of_Presenta2
Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies (Tables) | 3 Months Ended | |||
Mar. 31, 2014 | ||||
Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies [Abstract] | ' | |||
BioTime's ownership of outstanding shares of its subsidiaries | ' | |||
The following table reflects BioTime’s ownership, directly or through one or more subsidiaries, of the outstanding shares of its subsidiaries. | ||||
BioTime | ||||
Subsidiary | Field of Business | Ownership | Country | |
Asterias Biotherapeutics, Inc. | Research, development and commercialization of human therapeutic products from stem cells potentially in the fields of neurology, oncology, orthopedics, and cardiology | 71.60% | USA | |
ES Cell International Pte Ltd | Stem cell products for research, including clinical grade cell lines | 100% | Singapore | |
produced under cGMP | ||||
OncoCyte Corporation | Cancer diagnostics | 75.30% | USA | |
OrthoCyte Corporation | Orthopedic diseases, including chronic back pain and osteoarthritis | 100% | USA | |
Cell Cure Neurosciences Ltd. | Age-related macular degeneration | 62.50% | Israel | |
Multiple sclerosis | ||||
Parkinson’s disease | ||||
ReCyte Therapeutics, Inc. | Vascular disorders, including cardiovascular-related diseases, ischemic conditions, vascular injuries | 94.80% | USA | |
Stem cell-derived endothelial and cardiovascular related progenitor cells for research, drug testing, and therapeutics | ||||
BioTime Asia, Limited | Stem cell products for research | 81% | Hong Kong | |
LifeMap Sciences, Inc. | Genetic, disease, and stem cell databases | 73.20% | USA | |
LifeMap Sciences, Ltd. | Stem cell database | -1 | Israel | |
LifeMap Solutions, Inc. | Mobile health software | -1 | USA | |
-1 | LifeMap Sciences, Ltd. and LifeMap Solutions, Inc. are wholly-owned subsidiaries of LifeMap Sciences, Inc. |
Equipment_Tables
Equipment (Tables) | 3 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Equipment [Abstract] | ' | ||||||||
Equipment, furniture and fixtures | ' | ||||||||
At March 31, 2014 and December 31, 2013, equipment, furniture and fixtures were comprised of the following: | |||||||||
31-Mar-14 | December 31, | ||||||||
(unaudited) | 2013 | ||||||||
Equipment, furniture and fixtures | $ | 4,645,077 | $ | 4,431,586 | |||||
Accumulated depreciation | (1,685,927 | ) | (1,433,853 | ) | |||||
Equipment, net | $ | 2,959,150 | $ | 2,997,733 |
Intangible_assets_Tables
Intangible assets (Tables) | 3 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Intangible assets [Abstract] | ' | ||||||||
Intangible assets | ' | ||||||||
At March 31, 2014 and December 31, 2013, intangible assets and intangible assets net of amortization were comprised of the following: | |||||||||
31-Mar-14 | December 31, | ||||||||
(unaudited) | 2013 | ||||||||
Intangible assets | $ | 54,719,918 | $ | 54,719,918 | |||||
Accumulated amortization | (9,879,831 | ) | (8,511,833 | ) | |||||
Intangible assets, net | $ | 44,840,087 | $ | 46,208,085 |
Royalty_Obligation_and_Deferre1
Royalty Obligation and Deferred License Fees (Tables) | 3 Months Ended | ||||
Mar. 31, 2014 | |||||
Royalty Obligation and Deferred License Fees [Abstract] | ' | ||||
Amortization of deferred license fees | ' | ||||
As of March 31, 2014, future amortization of deferred license fees described above was as follows: | |||||
Year Ended | Deferred License | ||||
December 31, | Fees | ||||
2014 | $ | 83,615 | |||
2015 | 111,000 | ||||
2016 | 111,000 | ||||
2017 | 111,000 | ||||
Thereafter | 111,843 | ||||
Total | $ | 528,458 |
Accounts_Payable_and_Accrued_L1
Accounts Payable and Accrued Liabilities (Tables) | 3 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Accounts Payable and Accrued Liabilities [Abstract] | ' | ||||||||
Accounts payable and accrued liabilities | ' | ||||||||
At March 31, 2014 and December 31, 2013, accounts payable and accrued liabilities consisted of the following: | |||||||||
31-Mar-14 | December 31, | ||||||||
(unaudited) | 2013 | ||||||||
Accounts payable | $ | 2,527,330 | $ | 3,887,950 | |||||
Accrued bonuses | 229,905 | 600,000 | |||||||
Other accrued liabilities | 2,685,828 | 2,234,674 | |||||||
$ | 5,443,063 | $ | 6,722,624 |
Asset_Contribution_Agreement_T
Asset Contribution Agreement (Tables) | 3 Months Ended | ||||
Mar. 31, 2014 | |||||
Asset Contribution Agreement [Abstract] | ' | ||||
Assets Transferred by BioTime and Related Consideration | ' | ||||
The assets transferred by BioTime and the related consideration paid were recorded as follows: | |||||
Consideration transferred to BioTime: | |||||
Asterias Series B shares | $ | 52,164,568 | |||
Warrants to purchase Asterias Series B shares | 2,012,481 | ||||
Excess of contributed assets’ value over consideration | 4,800,063 | ||||
Total consideration issued | $ | 58,977,112 | |||
Assets transferred by BioTime: | |||||
BioTime common shares, at fair value | $ | 34,985,163 | |||
BioTime Warrants, at fair value | 18,276,406 | ||||
Cancellation of outstanding obligation to BioTime | 5,000,000 | ||||
Investment in affiliates, at cost | 415,543 | ||||
Geron asset acquisition related transaction costs paid by BioTime | 300,000 | ||||
Total assets transferred | $ | 58,977,112 | |||
Assets Acquired from Geron and Related Consideration | ' | ||||
The assets acquired from Geron and the related consideration were recorded as follows: | |||||
Consideration paid to Geron: | |||||
Asterias Series A shares, net of share issuance costs of $541,800 | $ | 15,121,222 | |||
Obligation to distribute BioTime Warrants | 18,276,406 | ||||
Transaction and other costs | 1,519,904 | ||||
Total consideration paid | $ | 34,917,532 | |||
Assets acquired from Geron (preliminary allocation): | |||||
Patents and other intellectual property rights related to hES cells | $ | 29,017,009 | |||
Deferred tax liability arising from difference in book versus tax basis on Geron intangible assets acquired | (11,558,243 | ) | |||
IPR&D expensed upon acquisition | 17,458,766 | ||||
Total assets and in-process research and development acquired | $ | 34,917,532 |
Unaudited_Pro_Forma_Interim_Fi1
Unaudited Pro Forma Interim Financial Information - Three Months Ended March 31, 2014 and 2013 (Tables) | 3 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Unaudited Pro Forma Interim Financial Information - Three Months Ended March 31, 2014 and 2013 [Abstract] | ' | ||||||||
Unaudited Pro Forma Information | ' | ||||||||
The following unaudited pro forma information gives effect to the asset acquisition through the Asset Contribution Agreement with Geron as if the transaction took place on January 1, 2013. The pro forma information does not necessarily reflect the results of operations that would have occurred had the entities been a single company during the periods presented. | |||||||||
Three Months Ended March 31, | |||||||||
2014 | 2013 | ||||||||
(Unaudited) | (Unaudited) | ||||||||
Revenues, net | $ | 934,721 | $ | 493,705 | |||||
Net loss available to common shareholders | $ | (8,099,014 | ) | $ | (22,572,852 | ) | |||
Net loss per common share – basic and diluted | $ | (0.14 | ) | $ | (0.38 | ) |
Organization_Basis_of_Presenta3
Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies (Details) (USD $) | 3 Months Ended | |||
Mar. 31, 2014 | Mar. 31, 2013 | Dec. 31, 2013 | ||
Income Taxes [Abstract] | ' | ' | ' | |
Deferred income tax benefit | $1,349,000 | ' | ' | |
Deferred income tax benefit, federal | 1,151,000 | ' | ' | |
Deferred income tax benefit, state taxes | 198,000 | ' | ' | |
Noncontrolling Interest [Line Items] | ' | ' | ' | |
Trade accounts receivable | 600,400 | ' | 575,900 | |
Grants receivable | 334,700 | ' | 539,300 | |
Allowance for doubtful accounts | 116,800 | ' | 116,800 | |
Property, Plant and Equipment [Line Items] | ' | ' | ' | |
Foreign currency translation (loss)/gain | -104,590 | 148,437 | ' | |
Unrealized loss | -2,650 | 0 | ' | |
Foreign currency transaction loss included in other income/(expense) | $10,212 | $21,977 | ' | |
Equipment [Member] | Minimum [Member] | ' | ' | ' | |
Property, Plant and Equipment [Line Items] | ' | ' | ' | |
Equipment useful life | '36 months | ' | ' | |
Equipment [Member] | Maximum [Member] | ' | ' | ' | |
Property, Plant and Equipment [Line Items] | ' | ' | ' | |
Equipment useful life | '120 months | ' | ' | |
Asterias Biotherapeutics [Member] | ' | ' | ' | |
Noncontrolling Interest [Line Items] | ' | ' | ' | |
BioTime Ownership (in hundredths) | 71.60% | ' | ' | |
ES Cell International Pte., Ltd. [Member] | ' | ' | ' | |
Noncontrolling Interest [Line Items] | ' | ' | ' | |
BioTime Ownership (in hundredths) | 100.00% | ' | ' | |
OncoCyte Corporation [Member] | ' | ' | ' | |
Noncontrolling Interest [Line Items] | ' | ' | ' | |
BioTime Ownership (in hundredths) | 75.30% | ' | ' | |
OrthoCyte Corporation [Member] | ' | ' | ' | |
Noncontrolling Interest [Line Items] | ' | ' | ' | |
BioTime Ownership (in hundredths) | 100.00% | ' | ' | |
Cell Cure Neurosciences, Ltd. [Member] | ' | ' | ' | |
Noncontrolling Interest [Line Items] | ' | ' | ' | |
BioTime Ownership (in hundredths) | 62.50% | ' | ' | |
ReCyte Therapeutics, Inc. [Member] | ' | ' | ' | |
Noncontrolling Interest [Line Items] | ' | ' | ' | |
BioTime Ownership (in hundredths) | 94.80% | ' | ' | |
BioTime Asia, Limited [Member] | ' | ' | ' | |
Noncontrolling Interest [Line Items] | ' | ' | ' | |
BioTime Ownership (in hundredths) | 81.00% | ' | ' | |
LifeMap Sciences, Inc. [Member] | ' | ' | ' | |
Noncontrolling Interest [Line Items] | ' | ' | ' | |
BioTime Ownership (in hundredths) | 73.20% | ' | ' | |
LifeMap Sciences, Ltd. [Member] | ' | ' | ' | |
Noncontrolling Interest [Line Items] | ' | ' | ' | |
BioTime Ownership (in hundredths) | ' | [1] | ' | ' |
LifeMap Solutions, Inc. [Member] | ' | ' | ' | |
Noncontrolling Interest [Line Items] | ' | ' | ' | |
BioTime Ownership (in hundredths) | ' | [1] | ' | ' |
Stock Options [Member] | ' | ' | ' | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ' | ' | ' | |
Anti-dilutive shares excluded from computation of diluted loss per share (in shares) | 5,491,301 | 4,771,301 | ' | |
Warrants [Member] | ' | ' | ' | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ' | ' | ' | |
Anti-dilutive shares excluded from computation of diluted loss per share (in shares) | 9,751,615 | 816,612 | ' | |
Treasury Shares [Member] | ' | ' | ' | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ' | ' | ' | |
Anti-dilutive shares excluded from computation of diluted loss per share (in shares) | 10,546,137 | 2,360,968 | ' | |
[1] | LifeMap Sciences, Ltd. and LifeMap Solutions, Inc. are wholly-owned subsidiaries of LifeMap Sciences, Inc. |
Inventory_Details
Inventory (Details) (USD $) | Mar. 31, 2014 | Dec. 31, 2013 |
Inventory [Abstract] | ' | ' |
Inventory of finished products on-site | $223,665 | $165,771 |
Inventory held by third party on consignment | $12,923 | $12,923 |
Equipment_Details
Equipment (Details) (USD $) | 3 Months Ended | ||
Mar. 31, 2014 | Mar. 31, 2013 | Dec. 31, 2013 | |
Equipment, furniture and fixtures [Abstract] | ' | ' | ' |
Equipment, furniture and fixtures | $4,645,077 | ' | $4,431,586 |
Accumulated depreciation | -1,685,927 | ' | -1,433,853 |
Equipment, net | 2,959,150 | ' | 2,997,733 |
Depreciation expense | $256,945 | $113,356 | ' |
Intangible_assets_Details
Intangible assets (Details) (USD $) | 3 Months Ended | ||
Mar. 31, 2014 | Mar. 31, 2013 | Dec. 31, 2013 | |
Intangible assets, net [Abstract] | ' | ' | ' |
Intangible assets | $54,719,918 | ' | $54,719,918 |
Accumulated amortization | -9,879,831 | ' | -8,511,833 |
Intangible assets, net | 44,840,087 | ' | 46,208,085 |
Intangible assets, useful life | '10 years | ' | ' |
Amortization of intangible assets | $1,367,998 | $642,573 | ' |
Royalty_Obligation_and_Deferre2
Royalty Obligation and Deferred License Fees (Details) | 3 Months Ended | 3 Months Ended | |||||||||||||||||
Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | |
USD ($) | WARF [Member] | WARF [Member] | WARF [Member] | Advanced Cell Technology, Inc. [Member] | Advanced Cell Technology Inc., with Kirin Sublicense I [Member] | Advanced Cell Technology Inc., with Kirin Sublicense II [Member] | Reproductive Genetics Institute [Member] | OncoCyte License From SBMRI [Member] | Cell Cure Neurosciences License From Hadasit [Member] | Cell Cure Neurosciences License From Hadasit [Member] | Cell Cure Neurosciences License From Hadasit [Member] | Cell Cure Neurosciences License From Hadasit [Member] | Teva License Agreement [Member] | Teva License Agreement [Member] | Teva License Agreement [Member] | BioTime License For The University of Utah [Member] | Asterias License From University of California [Member] | Asterias Sublicense From Geron [Member] | |
USD ($) | Minimum [Member] | Maximum [Member] | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | ILS | Minimum [Member] | Maximum [Member] | Phase I Clinical [Member] | Phase II Clinical [Member] | Phase III Clinical [Member] | USD ($) | USD ($) | USD ($) | |||
USD ($) | USD ($) | USD ($) | USD ($) | ||||||||||||||||
Finite-Lived Intangible Assets [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Intangible assets, useful life | '10 years | ' | ' | ' | '20 years | '20 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '3 years | ' | ' |
Royalty rate on sale of products and services (in hundredths) | ' | ' | 2.00% | 4.00% | 8.00% | 5.00% | 3.50% | ' | 4.00% | ' | ' | ' | ' | ' | ' | ' | 3.00% | 1.00% | ' |
Amended license agreement amount | ' | $295,000 | ' | ' | ' | ' | ' | ' | ' | ' | 249,058 | ' | ' | ' | ' | ' | ' | ' | $65,000 |
Annual license maintenance fee | ' | 25,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 10,000 |
Licensing fees paid | ' | ' | ' | ' | 250,000 | 200,000 | 50,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Maximum royalty payments | ' | ' | ' | ' | 1,000,000 | 600,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,500 | ' | ' |
Fees for sublicense (in hundredths) | ' | ' | ' | ' | ' | 20.00% | 20.00% | ' | 20.00% | 30.00% | ' | 10.00% | 30.00% | ' | ' | ' | ' | 7.50% | 1.00% |
Annual minimum royalty due | ' | ' | ' | ' | ' | ' | 50,000 | ' | ' | ' | ' | 100,000 | ' | ' | ' | ' | ' | 5,000 | ' |
Common shares issued (in shares) | ' | ' | ' | ' | ' | ' | ' | 32,259 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common shares issued, market value | ' | ' | ' | ' | ' | ' | ' | 50,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Fees for research use (in hundredths) | ' | ' | ' | ' | ' | ' | ' | ' | 10.00% | ' | 5.00% | ' | ' | ' | ' | ' | 30.00% | ' | ' |
Reduction in royalties (in hundredths) | ' | ' | ' | ' | ' | ' | ' | ' | 50.00% | ' | ' | ' | ' | ' | ' | ' | ' | 50.00% | ' |
Reimbursement to SBMRI for cost incurred (in hundredths) | ' | ' | ' | ' | ' | ' | ' | ' | 25.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Milestone payments | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 250,000 | 250,000 | 1,000,000 | 225,000 | ' | ' |
Sublicensing receipts for creditable milestone payments. | ' | ' | ' | ' | ' | ' | ' | ' | ' | 50,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Minimum royalty amount each year and thereafter | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 30,000 | ' | ' |
Payment upon issuance of first five license | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 5,000 | ' | ' |
Reduction for any patent that have licensed two or more | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,500 | ' | ' |
Notice period to terminate agreement | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '60 days | '90 days |
Amortization of deferred license fees [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
2014 | 83,615 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
2015 | 111,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
2016 | 111,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
2017 | 111,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Thereafter | 111,843 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Total | $528,458 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Accounts_Payable_and_Accrued_L2
Accounts Payable and Accrued Liabilities (Details) (USD $) | Mar. 31, 2014 | Dec. 31, 2013 |
Accounts Payable and Accrued Liabilities [Abstract] | ' | ' |
Accounts payable | $2,527,330 | $3,887,950 |
Accrued bonuses | 229,905 | 600,000 |
Other accrued liabilities | 2,685,828 | 2,234,674 |
Accounts payable and accrued liabilities | $5,443,063 | $6,722,624 |
Equity_Details
Equity (Details) (USD $) | 3 Months Ended | ||
Mar. 31, 2014 | Mar. 31, 2013 | Dec. 31, 2013 | |
Preferred Shares [Abstract] | ' | ' | ' |
Preferred shares, shares authorized (in shares) | 2,000,000 | ' | 2,000,000 |
Preferred shares, issued and outstanding (in shares) | 70,000 | ' | 0 |
Common Shares [Abstract] | ' | ' | ' |
Common shares, authorized (in shares) | 125,000,000 | ' | 125,000,000 |
Common shares, shares issued (in shares) | 69,617,329 | ' | 67,412,139 |
Common shares, shares outstanding (in shares) | 59,071,192 | ' | 56,714,424 |
Options exercised (in shares) | 45,000 | ' | ' |
Stock-based compensation expense | $801,554 | $691,946 | ' |
Stock options granted (in shares) | 1,205,000 | 1,090,000 | ' |
Warrants exercised (in shares) | 0 | ' | ' |
Series Preferred A Stock [Member] | ' | ' | ' |
Preferred Shares [Abstract] | ' | ' | ' |
Preferred shares, issued and outstanding (in shares) | 70,000 | ' | ' |
Preferred shares sold (in shares) | 70,000 | ' | ' |
Proceeds from sales of preferred shares | $3,500,000 | ' | ' |
Preferred stock dividend rate (in hundredths) | 3.00% | ' | ' |
Preferred share dividend (in dollars per shares) | $1.50 | ' | ' |
Share conversion price (in dollars per share) | $4 | ' | ' |
Common stock conversion ratio | 12.5 | ' | ' |
Period of option agreement | '5 years | ' | ' |
Asset_Contribution_Agreement_D
Asset Contribution Agreement (Details) (USD $) | 3 Months Ended | 0 Months Ended | 3 Months Ended | 3 Months Ended | ||||||||
Mar. 31, 2014 | Mar. 31, 2013 | Dec. 31, 2013 | Oct. 01, 2013 | Oct. 01, 2013 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | |
Common [Member] | Warrants [Member] | Asterias Biotherapeutics [Member] | Asterias Biotherapeutics [Member] | OrthoCyte Corporation [Member] | Cell Cure Neurosciences, Ltd. [Member] | Geron [Member] | Geron [Member] | Romulus Films, Ltd. [Member] | ||||
Common Class B [Member] | Common Class A [Member] | Common Class B [Member] | ||||||||||
Asset Contribution Agreement [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock issued during period (in shares) | ' | ' | ' | ' | ' | 8,902,077 | 21,773,340 | ' | ' | ' | 6,537,779 | 2,136,000 |
Common shares, par value (in dollars per share) | $0 | ' | $0 | ' | ' | ' | $0.00 | ' | ' | ' | $0.00 | ' |
Number of warrants issued (in shares) | ' | ' | ' | ' | ' | 8,000,000 | 3,150,000 | ' | ' | ' | ' | 350,000 |
Number of warrants to be issued by Asterias to Series A common shareholders (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 8,000,000 | ' |
Exercise price of warrant (in dollars per share) | ' | ' | ' | ' | $5 | $5 | $5 | ' | ' | ' | ' | ' |
Warrant expiration term | ' | ' | ' | ' | ' | '5 years | '3 years | ' | ' | ' | ' | ' |
Amount of contribution from investor | ' | ' | ' | ' | ' | $5,000,000 | ' | ' | ' | ' | ' | ' |
Percentage of subsidiary stock contributed (in hundredths) | ' | ' | ' | ' | ' | ' | ' | 10.00% | 6.00% | ' | ' | ' |
Proceeds from issuance of common shares | 8,182,559 | 11,699,340 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 5,000,000 |
Transaction costs allocated to issuance of equity | ' | ' | ' | ' | ' | ' | ' | ' | ' | 541,800 | ' | ' |
Fair value of shares issued (in dollars per share) | ' | ' | ' | ' | ' | ' | $2.40 | ' | ' | ' | $2.40 | ' |
Market value of BioTime common stock (in dollars per share) | ' | ' | ' | $3.93 | ' | ' | ' | ' | ' | ' | ' | ' |
Intangible assets, useful life | '10 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Royalty rate on net sales of products (in hundredths) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4.00% | ' |
Weighted-average assumptions [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Expected term | ' | ' | ' | ' | '5 years | ' | '3 years | ' | ' | ' | ' | ' |
Risk-free interest rate (in hundredths) | ' | ' | ' | ' | 1.42% | ' | 0.63% | ' | ' | ' | ' | ' |
Dividend yield (in hundredths) | ' | ' | ' | ' | 0.00% | ' | 0.00% | ' | ' | ' | ' | ' |
Expected volatility (in hundredths) | ' | ' | ' | ' | 77.63% | ' | 69.62% | ' | ' | ' | ' | ' |
Asterias Series B shares | ' | ' | ' | ' | ' | 52,164,568 | ' | ' | ' | ' | ' | ' |
Warrants to purchase Asterias Series B shares | ' | ' | ' | ' | ' | 2,012,481 | ' | ' | ' | ' | ' | ' |
Excess of contributed asset's value over consideration | ' | ' | ' | ' | ' | 4,800,063 | ' | ' | ' | ' | ' | ' |
Total consideration issued | ' | ' | ' | ' | ' | 58,977,112 | ' | ' | ' | 34,917,532 | ' | ' |
BioTIme common shares, at fair value | ' | ' | ' | ' | ' | 34,985,163 | ' | ' | ' | ' | ' | ' |
BioTime Warrants, at fair value | ' | ' | ' | ' | ' | 18,276,406 | ' | ' | ' | ' | ' | ' |
Cancellation of outstanding obligation to BioTime | ' | ' | ' | ' | ' | 5,000,000 | ' | ' | ' | ' | ' | ' |
Investment in affiliates, at cost | ' | ' | ' | ' | ' | 415,543 | ' | ' | ' | ' | ' | ' |
Geron asset acquisition related transaction costs paid by BioTime | ' | ' | ' | ' | ' | 300,000 | ' | ' | ' | ' | ' | ' |
Total assets transferred | ' | ' | ' | ' | ' | 58,977,112 | ' | ' | ' | ' | ' | ' |
Asterias Series A shares, net of issuance cost of $541,800 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 15,121,222 | ' | ' |
Obligation to distribute BioTIme Warrants | ' | ' | ' | ' | ' | ' | ' | ' | ' | 18,276,406 | ' | ' |
Transaction and other costs | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,519,904 | ' | ' |
Patents and other intellectual property rights related to hES cells | ' | ' | ' | ' | ' | ' | ' | ' | ' | 29,017,009 | ' | ' |
Deferred tax liability arising from difference in book versus tax basis on Geron intangible assets acquired | ' | ' | ' | ' | ' | ' | ' | ' | ' | -11,558,243 | ' | ' |
IPR&D expensed upon acquisition | ' | ' | ' | ' | ' | ' | ' | ' | ' | 17,458,766 | ' | ' |
Total assets and in-process research and development acquired | ' | ' | ' | ' | ' | ' | ' | ' | ' | $34,917,532 | ' | ' |
Unaudited_Pro_Forma_Interim_Fi2
Unaudited Pro Forma Interim Financial Information - Three Months Ended March 31, 2014 and 2013 (Details) (USD $) | 3 Months Ended | |
Mar. 31, 2014 | Mar. 31, 2013 | |
Unaudited Pro Forma Interim Financial Information - Three Months Ended March 31, 2014 and 2013 [Abstract] | ' | ' |
Revenues, net | $934,721 | $493,705 |
Net loss available to common shareholders | ($8,099,014) | ($22,572,852) |
Net loss per common share - basic and diluted (in dollars per share) | ($0.14) | ($0.38) |
Subsequent_Events_Details
Subsequent Events (Details) (USD $) | 3 Months Ended | 0 Months Ended | 1 Months Ended | 3 Months Ended | ||
Mar. 31, 2014 | Mar. 31, 2013 | 5-May-14 | 6-May-14 | 31-May-14 | Mar. 31, 2014 | |
Subsequent Event [Member] | Subsequent Event [Member] | Subsequent Event [Member] | Subsequent Event [Member] | |||
Tranche | Tranche | |||||
Intallment | ||||||
Subsequent Event [Line Items] | ' | ' | ' | ' | ' | ' |
Additional equity capital raised | $8,182,559 | $11,699,340 | ' | ' | $6,380,640 | ' |
Awarded grant amount | ' | ' | 224,911 | ' | ' | ' |
Overhead charges | ' | ' | ' | 1,000,000 | ' | ' |
Maximum percentages of current equity value of solutions at time of significant transaction (in hundredths) | ' | ' | ' | 5.00% | ' | ' |
Percentages of outstanding voting securities owns before transaction beneficially (in hundredths) | ' | ' | ' | 50.00% | ' | ' |
Common stock purchase during period (in shares) | ' | ' | ' | 2,500,000 | ' | ' |
Common stock purchase during period, value | ' | ' | ' | $5,000,000 | ' | ' |
Number of tranches | ' | ' | ' | 4 | ' | ' |
BioTime have option to purchase additional shares (in shares) | ' | ' | ' | ' | ' | 9,500,000 |
Share price (in dollars per share) | ' | ' | ' | ' | ' | $2 |
Number of tranches related to attainment of certain product development | ' | ' | ' | ' | ' | 2 |
Number of installments for each tranche | ' | ' | ' | ' | ' | 3 |
Number of trading days | ' | ' | ' | ' | ' | '20 days |